Antiseptic compositions
Patent Information
- Application Number
- HK62023081680
- Authority / Receiving Office
- HK · HK
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-06-22
- Filing Date
- 2023-10-30
- Publication Date
- 2026-09-11
AI Technical Summary
Existing hand or skin disinfectants contain alcohol-based compounds that are flammable, highly toxic, cause severe skin dryness and irritation, and have a short-lived disinfection effect. There is a need to improve antibacterial compositions to overcome these drawbacks.
An aqueous antibacterial composition is provided, comprising glycerol, caprylyl glycol and ethoxydiethylene glycol as main components to form a first component, the total of which is greater than 13%, and optionally ethoxydiethylene glycol, acrylates/C10-30, etc., to form a non-alcoholic antibacterial composition.
It achieves long-lasting antibacterial effect, low flammability, low toxicity, and low skin irritation, providing long-term antibacterial protection without the need for preservatives, and has the effect of effectively killing microorganisms in a short time.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of antimicrobial agents. More specifically, this invention relates to antimicrobial compositions that can be used to prepare skin or hand disinfectants. Background Technology
[0002] Antimicrobial agents used in the manufacture of hand or skin disinfectants play a vital role in current personal and public health practices. Alcohol-based compounds (such as ethanol or isopropanol) comprise a class of proven surface disinfectants and antiseptics widely used worldwide; however, their high flammability, toxicity, skin dryness, cracking, and irritation caused by repeated or prolonged use, and short-lived disinfection effects are also well-known drawbacks. Improved antimicrobial compositions are in dire need. Summary of the Invention
[0003] In view of the foregoing background, in some embodiments, the aim is to provide an alternative antimicrobial composition to overcome at least one of the disadvantages of the prior art.
[0004] Therefore, in some embodiments, one aspect provides an aqueous antibacterial composition. The composition comprises an aqueous mixture of a first component, the first component comprising: about 8.5%-16% glycerol by weight; about 0.45%-3% caprylyl glycol by weight; and a first ingredient; wherein the first ingredient is about 0.01%-0.1% acrylate / C10-30 by weight or about 1%-5% ethoxydiethylene glycol by weight. The glycerol, the caprylyl glycol, and the first ingredient together form the first component. The sum of the first components is greater than 13% by weight of the antibacterial composition.
[0005] In some exemplary embodiments, the composition is non-alcoholic, i.e., it contains little or no simple alcohols such as ethanol, isopropanol, or n-propanol. In some exemplary embodiments, the effective antibacterial component in the composition comprises glycerin, caprylyl glycol, acrylates / C10-30, or ethoxydiethylene glycol, or combinations thereof. In some exemplary embodiments, the composition is water-based. In some exemplary embodiments, the composition can be used to prepare skin or hand lotions, washes, or disinfectants. In some exemplary embodiments, the composition can be used as a disinfectant and can be used to prepare surface coatings for disinfecting objects.
[0006] It has now been unexpectedly discovered that at least some of the problems of the prior art can be overcome by the antimicrobial composition described in some exemplary embodiments, the antimicrobial composition comprising: about 8.5%-16% glycerol by weight and about 0.45%-3% caprylyl glycol by weight. In another exemplary embodiment, the sum of the glycerol and the caprylyl glycol is greater than 13% by weight of the antimicrobial composition. In another exemplary embodiment, the composition further comprises about 1%-5% ethoxydiethylene glycol by weight. In yet another exemplary embodiment, the composition further comprises about 0.01%-0.1% acrylate / C10-30 by weight.
[0007] Other exemplary embodiments will be described herein.
[0008] According to another aspect, a skin or hand sanitizer comprising the antimicrobial composition described herein is provided.
[0009] According to another aspect, an antimicrobial surface coating comprising the antimicrobial composition described herein is provided.
[0010] In another aspect, a method for preparing an antibacterial composition is provided.
[0011] In another aspect, use of an antibacterial composition is provided, wherein the composition comprises about 8.5%-16% glycerol by weight; about 0.45%-3% caprylyl glycol by weight; about 1%-5% ethoxydiethylene glycol by weight; and water.
[0012] This invention offers numerous advantages. In some embodiments, a non-alcohol-based antimicrobial composition is provided that has long-lasting antimicrobial efficacy and low flammability. In some embodiments, an antimicrobial composition is provided that has skin-moisturizing, low-toxicity, low-skin-irritant, and low-sensitizing properties. In some embodiments, an antimicrobial composition is provided that has low production costs. In some embodiments, the antimicrobial composition provides good antimicrobial efficacy (including but not limited to antibacterial, antifungal, and antiviral) and a short duration of action (i.e., effectively killing microorganisms within a short time period, such as 30 or 60 seconds). In some embodiments, no additional preservatives are required because the composition is self-preservative. In some embodiments, the composition forms an antimicrobial invisible film or "glove" on the skin or hands, providing long-term antimicrobial protection. Attached Figure Description
[0013] Figure 1A This is an image showing the face of patient 1 before using the exemplary composition according to an exemplary embodiment.
[0014] Figure 1B It shows the basis Figure 1AThe same exemplary embodiment is a picture of the face of the same patient after using the exemplary composition.
[0015] Figure 2A and Figure 2B The images show the left and right palms of patient 2 before using the exemplary composition, according to an exemplary embodiment.
[0016] Figure 2C and Figure 2D It shows the basis respectively. Figure 2A and Figure 2B Images of the left and right palms of the same patient after using the exemplary composition, as shown in the same exemplary embodiment.
[0017] Figure 3A This is an image showing the finger of patient 3 before using composition B according to an exemplary embodiment.
[0018] Figure 3B It shows the basis Figure 3A The same exemplary embodiment is shown in the image of the same patient's finger after using composition B. Detailed Implementation
[0019] As used herein and in the claims, “comprising” means to include the following elements, but does not exclude other elements. The terms “comprising” (or any related form such as “comprise” and “comprises”), “including” (or any related form such as “include” or “includes”), and “containing” (or any related form such as “contain” or “contains”) mean to include the following elements, but do not exclude other elements. It should be understood that for each embodiment using the terms “comprising” (or any related forms such as “comprise” and “comprises”), “including” (or any related forms such as “include” or “includes”), or “containing” (or any related forms such as “contain” or “contains”), this disclosure / application also includes alternative embodiments in which the terms “comprising”, “including”, or “contains” are replaced with “consistently consisting of” or “consistent with”. These alternative embodiments using “consistent with” or “consistently consisting of” are understood to be narrower embodiments of the “comprising”, “including”, or “contains” embodiments.
[0020] For example, alternative embodiments of "a composition comprising A, B, and C" are "a composition consisting of A, B, and C" and "a composition consisting essentially of A, B, and C". This disclosure / application includes these embodiments even if the latter two are not explicitly stated. Furthermore, it should be understood that the scope of the three embodiments listed above is different.
[0021] As used in the specification and claims, unless the context clearly indicates otherwise, the singular forms “a” and “an” also include the corresponding plural indicators. Thus, for example, the term “a polyol” can also refer to “multiple polyols”.
[0022] As used in the specification and claims, the terms "percentage by weight" or "% by weight" mean the percentage (%) of a component by weight relative to the total weight of the entire composition.
[0023] In the context of this specification, the terms “about,” “substantially,” and “approximately” indicate, as those skilled in the art will understand, a range of accuracy that still ensures the technical effect of the features under discussion. These terms typically indicate a deviation from the numerical values shown of 10%, and preferably 5%. For example, having about 20% by weight is equivalent to having 18%-22% or 19% to 21% by weight.
[0024] As used herein and in the claims, "disinfectant" means a reagent or chemical applied to inanimate objects to kill microorganisms.
[0025] As used herein and in the claims, "antiseptic" or "antiseptic agent" means a reagent or chemical applied to living tissue or skin to reduce the likelihood of infection caused by microorganisms present thereon. These microorganisms may be, but are not limited to, bacteria, viruses, and fungi (such as yeasts or molds).
[0026] As used herein and in the claims, "disinfectant" means a liquid, gel, or foam that is typically used to reduce infectious agents (such as microorganisms) on the skin or hands.
[0027] As used herein and in the claims, “simple alcohols” refers to one or more short-chain volatile or C1-C4 alcohols, such as ethanol, isopropanol (IPA), n-propanol, butanol, isobutanol or combinations thereof, and more particularly ethanol, isopropanol or combinations thereof, and especially ethanol.
[0028] As used herein and in the claims, "effective amount" means an amount that is effective at a concentration used to inactivate or at least significantly reduce the count of microorganisms such as bacteria, viruses and / or fungi.
[0029] As used herein and in the claims, "biological killing" means eliminating, rendering harmless, or controlling any harmful microorganism.
[0030] As used herein and in the claims, "polyol" means at least one diol or triol containing 3 to 8 carbon atoms (e.g., propylene glycol, 1,3-butanediol, 1,2-pentanediol, 1,2-octanediol (INCI name octanediol), 1,8-octanediol, 2-ethyl-1,3-hexanediol, glycerol (1,2,3-propanetriol), mannitol, sorbitol, or mixtures thereof). In some embodiments, the polyol is glycerol and octanediol.
[0031] As used herein and in the claims, "diol" means at least one monoether of diethylene glycol or triethylene glycol, or may be a polyalkylene glycol, such as methoxydiethylene glycol, ethoxydiethylene glycol, propoxydiethylene glycol, butoxydiethylene glycol, and triethylene glycol monopropyl ether. In some embodiments, the diol is ethoxydiethylene glycol.
[0032] As used herein and in the claims, “alkyl glycerol and / or its alkyl ester” refers to R4OCH2CH(OH)CH2OR5, wherein R4 is a straight-chain or branched alkyl group, and R5 is H, a straight-chain or branched alkyl group, or a straight-chain or branched alkyl acyl group. In some embodiments, R4 contains 6 to 24 carbon atoms, and R5 is H or contains 8 to 24 carbon atoms. In some embodiments, R4 is a straight-chain or branched alkyl group, and R5 is a straight-chain or branched alkyl acyl group. The terms “glycerine,” “glycerin,” and “glycerol” are used interchangeably.
[0033] As used herein, the terms “treat,” “treating,” or “treatment” refer to the following methods of: relieving, eliminating, or improving symptoms of a disease or condition in a preventive and / or therapeutic manner; preventing additional symptoms; improving or preventing the basal metabolic cause of symptoms; inhibiting a disease or condition; halting the progression of a disease or condition; alleviating a disease or condition; causing the remission of a disease or condition; reducing the condition caused by a disease or condition; or terminating the symptoms of a disease or condition.
[0034] For clarity, if a composition is described as "containing", "contains", or "contains" a specific component, it means that the composition contains said component, but may also contain other components.
[0035] As used herein and in the claims, "aromatic alcohol" refers to a compound containing a hydroxyl group bonded to a carbon atom that is part of an aromatic ring side chain. Examples of aromatic alcohols include, but are not limited to, phenoxyethanol, benzyl alcohol, and phenethyl alcohol. In some embodiments, the aromatic alcohol is an aromatic alcohol commonly used in dermatological and / or cosmetic compositions.
[0036] As used herein and in the claims, “panthenol” refers to an alcohol analogue of pantothenic acid (vitamin B5) and is therefore a previtamin of B5, with the chemical formula C9H10H2O. 19 NO4, and the IUPAC name is 2,4-dihydroxy-N-(3-hydroxypropyl)-3,3-dimethylbutyramide. In some exemplary embodiments, panthenol is in the D form or as a mixture of D and L (DL-panthenol).
[0037] As used herein and in the claims, “acrylate / C10-30” refers to an acrylate / C10-30 alkanol acrylate crosspolymer composed of a mixture of acrylic acid and methacrylic acid.
[0038] As used herein and in the claims, “sanitize” or “sanitizing” means the act of inactivating a harmful substance by killing it or neutralizing its harmful properties. Harmful substances include, but are not limited to, pathogens or infectious agents such as bacteria, viruses, and fungi. In some embodiments, the act of sanitizing reduces or prevents the spread of disease.
[0039] The compositions of the present invention can be used to disinfect hands, skin, mouth, lips, mucous membranes and skin appendages and / or disinfect surfaces such as food contact surfaces (e.g., cutting boards, knives, cutlery), instruments and foods such as fruits, peels and vegetables.
[0040] In some exemplary embodiments, the composition can be used to prepare skin or hand lotions, washes, or disinfectants. In some exemplary embodiments, the composition can be used to prepare surface coatings for disinfecting objects or preventing objects from being infected by infectious agents or exposed to infectious agents. In some exemplary embodiments, the composition is antibacterial. In some exemplary embodiments, the composition is antiviral. In some exemplary embodiments, the composition is antifungal.
[0041] In some exemplary embodiments, the composition is non-alcoholic, i.e., it contains no or substantially no alcohols, such as ethanol or isopropanol (isopropyl alcohol). In some exemplary embodiments, the composition comprises a first component selected from glycerol, caprylyl glycol, ethoxydiethylene glycol, and combinations thereof. In one exemplary embodiment, the first component in the composition is substantially composed of glycerol, caprylyl glycol, and ethoxydiethylene glycol. In some embodiments, the composition comprises the first component and water. In other embodiments, the composition consists substantially of the first component and water.
[0042] In some embodiments, the composition may further comprise one or more compounds. In some embodiments, the composition may also comprise one or more compounds selected from the group consisting of panthenol, sodium polyacrylate, phenoxyethanol, ethylhexyl stearate, tridecyl alcohol polyether-6, and ethylhexylglycerin and combinations thereof. In one exemplary embodiment, based on the antibacterial composition, the panthenol is 0.1% to 1% by weight; the sodium polyacrylate is 0.1% to 0.5% by weight; the phenoxyethanol is 0% to 1% by weight; the ethylhexyl stearate is 0% to 1% by weight; the tridecyl alcohol polyether-6 is 0% to 1% by weight; and the ethylhexylglycerin is 0% to 2% by weight.
[0043] In one exemplary embodiment, the composition is free of or substantially free of panthenol. In one exemplary embodiment, the composition is free of or substantially free of polyacrylate. In one exemplary embodiment, the composition is free of or substantially free of phenoxyethanol. In one exemplary embodiment, the composition is free of or substantially free of ethylhexyl stearate. In one exemplary embodiment, the composition is free of or substantially free of tridecyl alcohol polyether-6. In one exemplary embodiment, the composition is free of or substantially free of ethylhexylglycerin.
[0044] In some exemplary embodiments, the composition may contain water, which may optimize antimicrobial efficacy and / or moisturizing effects. In some exemplary embodiments, the composition is in the form of an aqueous composition and contains from 75% to 90% aqua (water). In other exemplary embodiments, the composition is in the form of an aqueous composition and contains from 10% to 90% by weight, from 20% to 90% by weight, from 30% to 90% by weight, from 40% to 90% by weight, from 50% to 90% by weight, from 60% to 90% by weight, from 70% to 90% by weight, from 75% to 90% by weight, from 80% to 90% by weight, and from 85% to 90% by weight of aqua (water) based on the total composition.
[0045] In some exemplary embodiments, the concentration of glycerol in the compositions of the present invention may include, but is not limited to, concentrations ranging from, for example, from about 5 wt% to about 20 wt%, or, for example, from about 8 wt% to about 16 wt%. In other exemplary embodiments, based on the entire composition, the concentration of glycerol in the composition includes, for example, concentrations ranging from, for example, from about 5 wt% to about 70 wt%, from about 5 wt% to about 65 wt%, from about 5 wt% to about 60 wt%, from about 5 wt% to about 55 wt%, from about 5 wt% to about 50 wt%, from about 5 wt% to about 45 wt%, from about 5 wt% to about 40 wt%, from about 5 wt% to about 35 wt%, from about 5 wt% to about 30 wt%, from about 5 wt% to about 25 wt%, from about 5 wt% to about 20 wt%, from about 5 wt% to about 15 wt%, from about 5 wt% to about 10 wt%, and from about 8 wt% to about 70 wt%. wt%, from about 8 wt% to about 65 wt%, from about 8 wt% to about 60 wt%, from about 8 wt% to about 65 wt%, from about 8 wt% to about 60 wt%, from about 8 wt% to about 55 wt%, from about 8 wt% to about 50 wt%, from about 8 wt% to about 45 wt%, from about 8 wt% to about 40 wt%, from about 8 wt% to about 35 wt%, from about 8 wt% to about 30 wt%, from about 8 wt% to about 25 wt%, from about 8 wt% to about 20 wt%, from about 8 wt% to about 15 wt%, from about 8 wt% to about 10 wt%, from about 10 wt% to about 70 wt%, from about 10 wt% to about 65 wt%, from about 10 wt% to about 60 wt%, from about 10 wt% to about 55 wt%, from about 10 wt% to about 50 wt%, from about 10 wt% to about 45 wt%, from about 10 wt% to about 40 wt%, from about 10 wt% to about 35 wt%, from about 10 wt% to about 30 wt%, from about 10 wt% to about 25 wt%, from about 10 wt% to about 20 wt%, from about 10 wt% to about 15 wt%, from about 12 wt% to about 70 wt%, from about 12 wt% to about 65 wt%, from about 12 wt% to about 60 wt%, from about 12 wt% to about 55 wt%, from about 12 wt% to about 50 wt%, from about 12 wt% to About 45 wt%, from about 12 wt% to about 40 wt%, from about 12 wt% to about 35 wt%, from about 12 wt% to about 30 wt%, from about 12 wt% to about 25 wt%, from about 12 wt% to about 20 wt%, from about 12 wt% to about 15 wt%, from about 14 wt% to about 70 wt%, from about 14 wt% to about 65 wt%, from about 14 wt% to about 60 wt%, from about 14 wt% to about 55 wt%, from about 14 wt% to about 50 wt%, from about 14 wt% to about 45 wt%, from about 14 wt% to about 40 wt%, from about 14 wt% to about 35 wt%, from about 14 wt% to about 30 wt%.From about 14 wt% to about 25 wt%, from about 14 wt% to about 20 wt%, from about 14 wt% to about 15 wt%, from about 16 wt% to about 70 wt%, from about 16 wt% to about 65 wt%, from about 16 wt% to about 60 wt%, from about 14 wt% to about 55 wt%, from about 16 wt% to about 50 wt%, from about 16 wt% to about 45 wt%, from about 16 wt% to about 40 wt%, from about 16 wt% to about 35 wt%, from about 16 wt% to about 30 wt%, from about 16 wt% to about 25 wt%, and from about 16 wt% to about 20 wt%.
[0046] In some exemplary embodiments, the concentration of octyl glycol in the compositions of the present invention may include, but is not limited to, concentrations ranging from about 0.4 wt% to about 3 wt%, for example, from about 0.45 wt% to about 3 wt%. In other exemplary embodiments, based on the entire composition, the concentration of octyl glycol in the composition includes, but is not limited to, concentrations ranging from about 0.4 wt% to about 20 wt%, from about 0.4 wt% to about 15 wt%, from about 0.4 wt% to about 10 wt%, from about 0.4 wt% to about 5 wt%, from about 0.4 wt% to about 3 wt%, from about 0.4 wt% to about 2 wt%, from about 0.4 wt% to about 1 wt%, from about 0.4 wt% to about 0.8 wt%, from about 0.4 wt% to about 0.6 wt%, from about 0.5 wt% to about 20 wt%, from about 0.5 wt% to about 15 wt%, from about 0.5 wt% to about 10 wt%, and from... From about 0.5 wt% to about 5 wt%, from about 0.5 wt% to about 3 wt%, from about 0.5 wt% to about 2 wt%, from about 0.5 wt% to about 1 wt%, from about 0.5 wt% to about 0.8 wt%, from about 0.5 wt% to about 0.6 wt%, from about 0.6 wt% to about 20 wt%, from about 0.6 wt% to about 15 wt%, from about 0.6 wt% to about 10 wt%, from about 0.6 wt% to about 5 wt%, from about 0.6 wt% to about 3 wt%, from about 0.6 wt% to about 2 wt%, from about 0.6 wt% to about 1 wt%, from about 0.6 wt% to about 0.8 wt%, from about 0.8 wt% to about 20 wt% %, from about 0.8 wt% to about 15 wt%, from about 0.8 wt% to about 10 wt%, from about 0.8 wt% to about 5 wt%, from about 0.8 wt% to about 3 wt%, from about 0.8 wt% to about 2 wt%, from about 0.8 wt% to about 1 wt%, from about 1 wt% to about 20 wt%, from about 1 wt% to about 15 wt%, from about 1 wt% to about 10 wt%, from about 1 wt% to about 5 wt%, from about 1 wt% to about 3 wt%, from about 1 wt% to about 2 wt%, from about 1 wt% to about 1.5 wt%, from about 1.2 wt% to about 20 wt%, from about 1.2 wt% to about 15 wt%, from about 1.2 wt% to About 10 wt%, from about 1.2 wt% to about 5 wt%, from about 1.2 wt% to about 3 wt%, from about 1.2 wt% to about 2 wt%, from about 1.2 wt% to about 1 wt%, from about 1.2 wt% to about 0.8 wt%, from about 1.2 wt% to about 1.0 wt%, from about 1.4 wt% to about 20 wt%, from about 1.4 wt% to about 15 wt%, from about 1.4 wt% to about 10 wt%, from about 1.4 wt% to about 5 wt%, from about 1.4 wt% to about 3 wt%, from about 1.4 wt% to about 2 wt%, from about 1.4 wt% to about 1.8 wt%, from about 1.4 wt% to about 1.6 wt%, from about 1.From 6 wt% to about 20 wt%, from about 1.6 wt% to about 15 wt%, from about 1.6 wt% to about 10 wt%, from about 1.6 wt% to about 5 wt%, from about 1.6 wt% to about 3 wt%, from about 1.6 wt% to about 2 wt%, from about 1.6 wt% to about 1.8 wt%, from about 1.8 wt% to about 20 wt%, from about 1.8 wt% to about 15 wt%, from about 1.8 wt% to about 10 wt%, from about 1.8 wt% to about 5 wt%, from about 1.8 wt% to about 3 wt%, from about 1.8 wt% to about 20 ... From about 2 wt%, from about 2 wt% to about 20 wt%, from about 2 wt% to about 15 wt%, from about 2 wt% to about 10 wt%, from about 2 wt% to about 5 wt%, from about 2 wt% to about 3 wt%, from about 2 wt% to about 2.5 wt%, from about 2.2 wt% to about 20 wt%, from about 2.2 wt% to about 15 wt%, from about 2.2 wt% to about 10 wt%, from about 2.2 wt% to about 5 wt%, from about 2.2 wt% to about 3 wt%, from about 2.4 wt% to about 20 wt%, from about 2.4 wt% to about 2.4 wt%. From about 2.4 wt% to about 15 wt%, from about 2.4 wt% to about 10 wt%, from about 2.4 wt% to about 5 wt%, from about 2.4 wt% to about 3 wt%, from about 2.4 wt% to about 2.5 wt%, from about 2.6 wt% to about 20 wt%, from about 2.6 wt% to about 15 wt%, from about 2.6 wt% to about 10 wt%, from about 2.6 wt% to about 5 wt%, from about 2.6 wt% to about 3 wt%, from about 2.6 wt% to about 2.8 wt%, from about 2.8 wt% to about 20 wt%, from about 2.8 wt% to about 2.8 wt%. Concentrations ranging from about 2.8 wt% to about 15 wt%, from about 2.8 wt% to about 5 wt%, from about 2.8 wt% to about 3 wt%, from about 3 wt% to about 20 wt%, from about 3 wt% to about 15 wt%, from about 3 wt% to about 10 wt%, from about 3 wt% to about 5 wt%, from about 3 wt% to about 4 wt%, from about 3 wt% to about 3.5 wt%, from about 3 wt% to about 3.4 wt%, from about 3 wt% to about 3.3 wt%, and from about 3 wt% to about 3.2 wt%.
[0047] In some exemplary embodiments, the concentration of ethoxydiethylene glycol in the compositions of the present invention may include, but is not limited to, concentrations ranging from, for example, from about 1 wt% to about 5 wt%, or, for example, from about 2 wt% to about 4 wt%. In other exemplary embodiments, based on the entire composition, the concentration of ethoxydiethylene glycol in the composition includes, for example, concentrations ranging from, for example, from about 1 wt% to about 20 wt%, from about 1 wt% to about 15 wt%, from about 1 wt% to about 10 wt%, from about 1 wt% to about 5 wt%, from about 1 wt% to about 3 wt%, from about 1 wt% to about 2 wt%, from about 1 wt% to about 1.8 wt%, from about 1 wt% to about 1.6 wt%, from about 1 wt% to about 1.4 wt%, and from about 1 wt% to about 2 wt%. From about 1.2 wt%, from 2 wt% to about 20 wt%, from about 2 wt% to about 15 wt%, from about 2 wt% to about 10 wt%, from about 2 wt% to about 5 wt%, from about 2 wt% to about 3 wt%, from about 2 wt% to about 2.8 wt%, from about 2 wt% to about 2.6 wt%, from about 2 wt% to about 2.4 wt%, from about 2 wt% to about 2.2 wt%, from about 3 wt% to about 20 wt%, from about 3 wt% to about 15 wt%, from about 3 wt% to about 10 wt% %, from about 3 wt% to about 5 wt%, from about 3 wt% to about 4 wt%, from about 3 wt% to about 3.8 wt%, from about 3 wt% to about 3.6 wt%, from about 3 wt% to about 3.4 wt%, from about 3 wt% to about 3.2 wt%, from about 4 wt% to about 20 wt%, from about 4 wt% to about 15 wt%, from about 4 wt% to about 10 wt%, from about 4 wt% to about 5 wt%, from about 4 wt% to about 4.8 wt%, from about 4 wt% to about 4.6 wt%, from about Concentrations ranging from 4 wt% to about 4.4 wt%, from about 4 wt% to about 4.2 wt%, from about 5 wt% to about 20 wt%, from about 5 wt% to about 15 wt%, from about 5 wt% to about 10 wt%, from about 5 wt% to about 8 wt%, from about 5 wt% to about 7 wt%, from about 5 wt% to about 6 wt%, from about 5 wt% to about 5.8 wt%, from about 5 wt% to about 5.6 wt%, from about 5 wt% to about 5.4 wt%, and from about 5 wt% to about 5.2 wt%. In some exemplary embodiments, the composition does not contain ethoxydiethylene glycol.
[0048] In some exemplary embodiments, the concentration of sodium polyacrylate in the compositions of the present invention may include, but is not limited to, a concentration in the range of about 0.1 wt% to about 0.5 wt%, such as about 0.1 wt%, 0.2 wt%, 0.3 wt%, 0.4 wt%, and 0.5 wt%. In some exemplary embodiments, the compositions do not contain sodium polyacrylate.
[0049] In some exemplary embodiments, the concentration of ethylhexylglycerol in the compositions of the present invention may include, but is not limited to, concentrations ranging from about 0 wt% to about 2 wt%, such as about 0.1 wt%, 0.2 wt%, 0.3 wt%, 0.4 wt%, 0.5 wt%, 0.6 wt%, 0.7 wt%, 0.8 wt%, 0.9 wt%, 1.0 wt%, 1.1 wt%, 1.2 wt%, 1.3 wt%, 1.4 wt%, 1.5 wt%, 1.6 wt%, 1.7 wt%, 1.8 wt%, 1.9 wt%, and 2.0 wt%. In some exemplary embodiments, the compositions do not contain ethylhexylglycerol.
[0050] In some exemplary embodiments, the concentration of panthenol in the compositions of the present invention may include, but is not limited to, concentrations ranging from about 0.1 wt% to about 1 wt%, such as about 0.1 wt%, 0.2 wt%, 0.3 wt%, 0.4 wt%, 0.5 wt%, 0.6 wt%, 0.7 wt%, 0.8 wt%, 0.9 wt%, and 1.0 wt%. In some exemplary embodiments, the compositions do not contain panthenol.
[0051] In some exemplary embodiments, the concentration of phenoxyethanol in the compositions of the present invention may include, but is not limited to, concentrations ranging from about 0 wt% to about 1 wt%, such as about 0.1 wt%, 0.2 wt%, 0.3 wt%, 0.4 wt%, 0.5 wt%, 0.6 wt%, 0.7 wt%, 0.8 wt%, 0.9 wt%, and 1.0 wt%. In some exemplary embodiments, the compositions do not contain phenoxyethanol.
[0052] In some exemplary embodiments, the concentration of ethylhexyl stearate in the compositions of the present invention may include, but is not limited to, concentrations ranging from about 0 wt% to about 1 wt%, such as about 0.1 wt%, 0.2 wt%, 0.3 wt%, 0.4 wt%, 0.5 wt%, 0.6 wt%, 0.7 wt%, 0.8 wt%, 0.9 wt%, and 1.0 wt%. In some exemplary embodiments, the compositions do not contain ethylhexyl stearate.
[0053] In some exemplary embodiments, the concentration of tridecyl alcohol polyether-6 in the compositions of the present invention may include, but is not limited to, concentrations ranging from about 0 wt% to about 1 wt%, such as about 0.1 wt%, 0.2 wt%, 0.3 wt%, 0.4 wt%, 0.5 wt%, 0.6 wt%, 0.7 wt%, 0.8 wt%, 0.9 wt%, and 1.0 wt%. In some exemplary embodiments, the compositions do not contain tridecyl alcohol polyether-6.
[0054] In some exemplary embodiments, the concentration of carbomer in the compositions of the present invention may include, but is not limited to, concentrations ranging from about 0 wt% to about 2 wt%, such as about 0.1 wt%, 0.2 wt%, 0.3 wt%, 0.4 wt%, 0.5 wt%, 0.6 wt%, 0.7 wt%, 0.8 wt%, 0.9 wt%, 1.0 wt%, 1.1 wt%, 1.2 wt%, 1.3 wt%, 1.4 wt%, 1.5 wt%, 1.6 wt%, 1.7 wt%, 1.8 wt%, 1.9 wt%, and 2.0 wt%. In some exemplary embodiments, the compositions do not contain carbomer.
[0055] In some exemplary embodiments, the concentration of acrylate / C10-30 (acrylate / C10-30 alkanol acrylate crosspolymer) in the compositions of the present invention may include, but is not limited to, concentrations ranging from about 0 wt% to about 0.1 wt%, such as about 0.01 wt%, 0.02 wt%, 0.03 wt%, 0.04 wt%, 0.05 wt%, 0.06 wt%, 0.07 wt%, 0.08 wt%, 0.9 wt%, and 0.1 wt%. In some exemplary embodiments, the compositions do not contain acrylate / C10-30.
[0056] In some exemplary embodiments, the concentration of 1,2-hexanediol in the compositions of the present invention may include, but is not limited to, concentrations ranging from about 0 wt% to about 2 wt%, such as about 0.1 wt%, 0.2 wt%, 0.3 wt%, 0.4 wt%, 0.5 wt%, 0.6 wt%, 0.7 wt%, 0.8 wt%, 0.9 wt%, 1.0 wt%, 1.1 wt%, 1.2 wt%, 1.3 wt%, 1.4 wt%, 1.5 wt%, 1.6 wt%, 1.7 wt%, 1.8 wt%, 1.9 wt%, and 2.0 wt%. In some exemplary embodiments, the compositions do not contain 1,2-hexanediol.
[0057] In some exemplary embodiments, the concentration of sodium dodecylbenzenesulfonate in the compositions of the present invention may include, but is not limited to, concentrations in the range of from about 0 wt% to about 0.01 wt%, such as about 0.001 wt%, 0.002 wt%, 0.003 wt%, 0.004 wt%, 0.005 wt%, 0.006 wt%, 0.007 wt%, 0.008 wt%, 0.009 wt%, and 0.010 wt%. In some exemplary embodiments, the compositions do not contain sodium dodecylbenzenesulfonate.
[0058] In some exemplary embodiments, the concentration of sodium citrate in the compositions of the present invention may include, but is not limited to, concentrations in the range of from about 0 wt% to about 0.001 wt%, such as about 0.0001 wt%, 0.0002 wt%, 0.0003 wt%, 0.0004 wt%, 0.0005 wt%, 0.0006 wt%, 0.0007 wt%, 0.0008 wt%, 0.0009 wt%, and 0.0010 wt%. In some exemplary embodiments, the compositions do not contain sodium citrate.
[0059] In some exemplary embodiments, the concentration of silver sulfate in the compositions of the present invention may include, but is not limited to, concentrations in the range of from about 0 wt% to about 0.001 wt%, such as about 0.00005 wt%, about 0.0001 wt%, about 0.00015 wt%, 0.0002 wt%, about 0.00025 wt%, 0.0003 wt%, about 0.00035 wt%, 0.0004 wt%, about 0.00045 wt%, 0.0005 wt%, about 0.00055 wt%, 0.0006 wt%, about 0.00065 wt%, 0.0007 wt%, about 0.00075 wt%, 0.0008 wt%, about 0.00085 wt%, 0.0009 wt%, about 0.00095 wt%, and 0.0010 wt%. In some exemplary embodiments, the composition does not contain silver sulfate.
[0060] In some exemplary embodiments, the concentration of silver in the compositions of the present invention may include, but is not limited to, concentrations in the range from about 0 wt% to about 0.001 wt%, such as about 0.00005 wt%, about 0.0001 wt%, about 0.00015 wt%, 0.0002 wt%, about 0.00025 wt%, 0.0003 wt%, about 0.00035 wt%, 0.0004 wt%, about 0.00045 wt%, 0.0005 wt%, about 0.00055 wt%, 0.0006 wt%, about 0.00065 wt%, 0.0007 wt%, about 0.00075 wt%, 0.0008 wt%, about 0.00085 wt%, 0.0009 wt%, about 0.00095 wt%, and 0.0010 wt%. In some exemplary embodiments, the compositions do not contain silver.
[0061] In some exemplary embodiments, the concentration of benzyl alcohol in the compositions of the present invention may include, but is not limited to, concentrations ranging from about 0 wt% to about 1 wt%, such as about 0.1 wt%, 0.2 wt%, 0.3 wt%, 0.4 wt%, 0.5 wt%, 0.6 wt%, 0.7 wt%, 0.8 wt%, 0.9 wt%, and 1.0 wt%. In some exemplary embodiments, the compositions do not contain benzyl alcohol.
[0062] In some embodiments, the composition may further comprise one or more additives, such as humectants or wetting agents, bactericides or antibacterial agents, antioxidants, colorants, thickeners, buffers, solvents, salts, polymers, essential oils, animal or plant extracts, gelling agents, silicones, vitamins, viscosity reducers, fragrances, preservatives, penetration enhancers, acidity regulators, emulsifiers, irritants, surfactants, ceramides, sunscreen ingredients, emollients, skin conditioning agents, etc. Exemplary additives include, but are not limited to, acrylates / C10-30 (acrylates / C10-30 alkanol acrylate crosspolymers), carbomer, 1,2-hexanediol, sodium dodecylbenzenesulfonate, and sodium citrate.
[0063] Non-limiting examples of preservatives include, but are not limited to, sodium benzoate, benzoic acid, sorbitol, phenoxyethanol, phenethyl alcohol, benzalkonium chloride, EDTA, benzyl alcohol, potassium sorbate, p-hydroxybenzoate, chlorhexidine gluconate, and mixtures thereof.
[0064] Non-limiting examples of emollients include, but are not limited to, petrolatum (white paraffin), castor oil, cetyl alcohol, cetearyl alcohol, cocoa butter, isopropyl myristate, isopropyl palmitate, lanolin, liquid paraffin, polyethylene glycol, shea butter, silicone oil, stearic acid, and stearyl alcohol.
[0065] Non-limiting examples of antioxidants include, but are not limited to, vitamin C and vitamin E.
[0066] Optionally, an anti-sticking agent may be added to the compositions of the present invention in an amount that effectively reduces the tack or adhesiveness associated with wetting agents and / or gelling agents.
[0067] In some embodiments, the composition may optionally further comprise at least one additional antimicrobial agent, antiviral agent, or antifungal agent, or a combination thereof. Non-limiting examples of such agents include, but are not limited to, silver sulfate, silver, and benzyl alcohol.
[0068] In some embodiments, the composition is unique in that the combination of its components provides good antimicrobial properties (e.g., meeting the requirements of EN 1276) and / or satisfactory toxicological results (e.g., meeting the requirements of a toxicological risk assessment (TRA) based on general principles of toxicology and with reference to EU and US cosmetic regulations and standards).
[0069] Numbered Examples - Group 1
[0070] 1. An aqueous antibacterial composition, said aqueous antibacterial composition comprising:
[0071] (a) Approximately 8.5%–16% glycerol by weight;
[0072] (b) Approximately 0.45% to 3% by weight of octyl glycol;
[0073] (c) Approximately 0.01%-0.1% by weight of acrylates / C10-30;
[0074] The glycerol, caprylyl glycol, and acrylate / C10-30 together form a first component, wherein the first component constitutes more than about 13% by weight of the antibacterial composition.
[0075] 2. An aqueous antibacterial composition, said aqueous antibacterial composition comprising:
[0076] (a) Approximately 8.5%–16% glycerol by weight;
[0077] (b) about 0.45%-3% by weight of octyl glycol; and
[0078] (c) Approximately 1%-5% by weight of ethoxydiethylene glycol;
[0079] The glycerol, octyl glycol, and ethoxydiethylene glycol together form a first component, wherein the first component constitutes more than about 13% by weight of the antibacterial composition.
[0080] 3. The aqueous antibacterial composition as described in Example 1 or 2, wherein the first component further comprises about 0%-1% phenoxyethanol by weight.
[0081] 4. The aqueous antibacterial composition as described in Example 2, wherein, based on the antibacterial composition, the glycerol is about 8.5%-10.7% by weight, the caprylyl glycol is about 0.6%-1.3% by weight, and the ethoxydiethylene glycol is about 2.1%-4.1% by weight.
[0082] 5. The aqueous antimicrobial composition as described in Example 1 or 2, wherein the first component is less than about 25% by weight of the antimicrobial composition and is substantially free of alkyl glycerols and / or their alkyl esters.
[0083] 6. The aqueous antimicrobial composition as described in Example 1 or 2, wherein the first component is less than about 25% by weight of the antimicrobial composition and is substantially free of ethylhexylglycerin.
[0084] 7. The aqueous antibacterial composition as described in Example 1 or 2, further comprising one or more compounds selected from the group consisting of panthenol, sodium polyacrylate, phenoxyethanol, ethylhexyl stearate and tridecyl alcohol polyether-6.
[0085] 8. The aqueous antibacterial composition as described in Example 7, wherein: based on the antibacterial composition,
[0086] (a) The panthenol is about 0.1% to 1% by weight;
[0087] (b) The sodium polyacrylate is approximately 0.1% to 0.5% by weight;
[0088] (c) The phenoxyethanol is about 0% to 1% by weight;
[0089] (d) The ethylhexyl stearate is approximately 0% to 1% by weight; and
[0090] (e) The tridecyl alcohol polyether-6 is about 0% to 1% by weight.
[0091] 9. The aqueous antibacterial composition as described in any of the foregoing embodiments, wherein the composition is substantially free of sodium polyacrylate.
[0092] 10. The aqueous antibacterial composition as described in any of the foregoing embodiments, wherein the composition is substantially free of simple alcohols.
[0093] 11. The aqueous antibacterial composition as described in any of the foregoing embodiments, wherein the composition further comprises about 0.01%-0.1% of acrylate / C10-30.
[0094] 12. The aqueous antibacterial composition as described in any of the foregoing embodiments, wherein the first component further comprises about 0%-2% ethylhexylglycerin.
[0095] 13. The aqueous antibacterial composition as described in any of the foregoing embodiments, wherein the composition further comprises about 0.1% to 1% carbomer.
[0096] 14. The aqueous antibacterial composition as described in any of the foregoing embodiments, wherein the composition further comprises about 1% to 5% of 1,2-hexanediol.
[0097] 15. The aqueous antibacterial composition as described in any of the foregoing embodiments, wherein the composition further comprises one or more of the following: sodium dodecylbenzenesulfonate, sodium citrate, silver sulfate, and silver.
[0098] 16. The aqueous antibacterial composition as described in any of the foregoing embodiments, wherein the composition further comprises about 0%-5% benzyl alcohol.
[0099] 17. The aqueous antibacterial composition as described in any of the foregoing embodiments, wherein the composition has the same or higher biocidal efficacy and durable bacterial inhibition compared to 75% isopropanol.
[0100] 18. The aqueous antimicrobial composition as described in any of the foregoing embodiments, wherein the composition is capable of exhibiting greater than 4 log10 microbial killing within 5 minutes.
[0101] 19. The aqueous antibacterial composition as described in any of the foregoing embodiments, wherein the composition is capable of exhibiting a virus-killing effect of greater than 6 log10 within 30 seconds or 1 minute.
[0102] 20. The aqueous antibacterial composition as described in any of the foregoing embodiments, wherein the composition effectively inhibits COVID-19 within 5 minutes.
[0103] 21. The aqueous antibacterial composition as described in any of the foregoing embodiments, wherein the composition is substantially non-evaporating.
[0104] 22. The aqueous antibacterial composition as described in any of the foregoing embodiments, wherein the composition remains on the surface to which it is applied for at least 1 minute or at least 5 minutes.
[0105] 23. The aqueous antimicrobial composition as described in Example 18, wherein the microorganism is bacteria, fungi, yeast, mold, virus, or a combination thereof.
[0106] 24. The aqueous antimicrobial composition as described in Example 18, wherein the microorganism is a virus.
[0107] 25. The aqueous antibacterial composition as described in Example 24, wherein the virus is H3N2 influenza A virus.
[0108] 26. The aqueous antimicrobial composition as described in Example 24, wherein the virus is a human coronavirus.
[0109] 27. The aqueous antimicrobial composition as described in Example 26, wherein the human coronavirus is strain 229E or COVID-19.
[0110] 28. The aqueous antimicrobial composition as described in Example 18, wherein the microorganism is one or more of Escherichia coli, Staphylococcus aureus, Candida albicans, H3N2 influenza A virus, or human viral coronavirus.
[0111] 29. A skin or hand sanitizer comprising an aqueous antibacterial composition as described in any of the foregoing embodiments.
[0112] 30. An aqueous antibacterial surface coating comprising an aqueous antibacterial composition as described in any of the foregoing embodiments.
[0113] 31. A woven or nonwoven wipe, sponge, or paper towel comprising an aqueous antibacterial composition as described in any of the foregoing embodiments.
[0114] 32. An aqueous antibacterial composition, said aqueous antibacterial composition comprising:
[0115] (a) Approximately 8%-20% polyols by weight;
[0116] (b) about 1%-5% by weight of diols and / or about 0%-5% by weight of aromatic alcohols;
[0117] The total amount of the polyol, the diol, and the aromatic alcohol is about 13%-25% by weight of the composition; and
[0118] The composition is substantially free of alkylglycerols and their alkyl esters, and free of simple alcohols.
[0119] 33. The aqueous antibacterial composition as described in Example 26, wherein the polyol is about 8.5%-16% glycerol by weight and about 0.45%-3% caprylyl glycol by weight.
[0120] 34. The aqueous antibacterial composition as described in Example 26, wherein the diol is about 2.06%-4.12% ethoxydiethylene glycol.
[0121] 35. The aqueous antibacterial composition as described in Example 26, wherein the aromatic alcohol is one or more of phenoxyethanol, benzyl alcohol, and phenethyl alcohol.
[0122] 36. The aqueous antibacterial composition as described in Example 27, wherein the polyol is about 1%-2% 1,2-hexanediol.
[0123] 37. The aqueous antibacterial composition as described in Example 27, further comprising silver and / or silver ions.
[0124] 38. Use of the aqueous antibacterial composition as described in any of the foregoing embodiments in the manufacture of disinfectants.
[0125] 39. An aqueous non-alcoholic disinfectant, said aqueous non-alcoholic disinfectant comprising:
[0126] (a) Approximately 8.5%–16% glycerol by weight;
[0127] (b) Approximately 0.45% to 3% by weight of octyl glycol;
[0128] (c) Approximately 0.01%-0.1% by weight of acrylates / C10-30; and
[0129] The total amount of the glycerol, caprylyl glycol, and acrylates / C10-30 is approximately 13%-25% by weight of the disinfectant.
[0130] 40. The aqueous non-alcoholic disinfectant as described in Example 39, wherein the disinfectant further comprises one or more compounds selected from the group consisting of: about 0%-1% phenoxyethanol by weight, about 0.1%-1% panthenol by weight, about 0%-0.5% sodium polyacrylate by weight, about 0%-1% ethylhexyl stearate by weight, about 0%-1% tridecyl alcohol polyether-6 by weight, and about 0.1%-1% carbomer by weight.
[0131] 41. The aqueous non-alcoholic disinfectant as described in Example 39, wherein the disinfectant is substantially free of alkyl glycerols and / or their alkyl esters.
[0132] 42. The aqueous non-alcoholic disinfectant as described in Example 39, wherein the disinfectant is substantially free of ethylhexylglycerin.
[0133] 43. The aqueous non-alcoholic disinfectant as described in Example 39, wherein the total amount of glycerol, the caprylyl glycol, and the acrylate / C10-30 is about 15% by weight.
[0134] 44. The aqueous non-alcoholic disinfectant as described in Example 43, further comprising about 0.3% panthenol, about 0.5% phenoxyethanol, and about 0.8% carbomer by weight.
[0135] 45. The aqueous non-alcoholic disinfectant as described in Example 43, further comprising about 0.3% panthenol, about 0.4% sodium polyacrylate, about 0.2% ethylhexyl stearate, about 0.07% tridecyl alcohol polyether-6, and about 0.1% carbomer by weight.
[0136] 46. An aqueous non-alcoholic disinfectant, said aqueous non-alcoholic disinfectant comprising:
[0137] (a) Approximately 8.5%–16% glycerol by weight;
[0138] (b) about 0.45%-3% by weight of octyl glycol; and
[0139] (c) Approximately 1%-5% by weight of ethoxydiethylene glycol;
[0140] The total amount of the glycerol, caprylyl glycol, and ethoxydiethylene glycol is approximately 13%-25% by weight of the disinfectant.
[0141] 47. The aqueous non-alcoholic disinfectant as described in Example 46, wherein the total amount of glycerol, octyl glycol and ethoxydiethylene glycol is about 19% by weight.
[0142] 48. The aqueous non-alcoholic disinfectant as described in Example 46 further comprises about 0.5% by weight of phenoxyethanol, about 0.3% by weight of panthenol, about 0.2% by weight of sodium polyacrylate, about 0.09% by weight of ethylhexyl stearate, about 0.03% by weight of tridecyl alcohol polyether-6, and about 0.9% by weight of ethylhexylglycerin.
[0143] 49. The aqueous non-alcoholic disinfectant as described in Example 46, further comprising about 0.3% panthenol by weight, about 0.2% sodium polyacrylate by weight, about 0.11% ethylhexyl stearate by weight, about 0.04% tridecyl alcohol polyether-6 by weight, about 0.9% ethylhexylglycerin by weight, and about 1.5% 1,2-hexanediol by weight.
[0144] 50. The aqueous non-alcoholic disinfectant as described in Example 46, wherein the total amount of glycerol, octyl glycol and ethoxydiethylene glycol is about 16.4% by weight.
[0145] 51. The aqueous non-alcoholic disinfectant as described in Example 46 further comprises about 0.5% by weight of phenoxyethanol, about 0.3% by weight of panthenol, about 0.3% by weight of sodium polyacrylate, about 0.09% by weight of ethylhexyl stearate, and about 0.03% by weight of tridecyl alcohol polyether-6.
[0146] 52. The aqueous non-alcoholic disinfectant as described in Example 47 further comprises about 0.005% sodium dodecylbenzenesulfonate, about 0.0006% sodium citrate, about 0.00015% silver sulfate, and about 0.00015% silver by weight.
[0147] 53. The aqueous non-alcoholic disinfectant as described in Example 52 further comprises about 1% benzyl alcohol by weight.
[0148] 54. The aqueous non-alcoholic disinfectant as described in Example 42, wherein the total amount of glycerol, octyl glycol and ethoxydiethylene glycol is about 20.8% by weight.
[0149] 55. The aqueous non-alcoholic disinfectant as described in Example 54, further comprising about 0.5% by weight of phenoxyethanol, about 0.3% by weight of panthenol, about 0.2% by weight of sodium polyacrylate, about 0.11% by weight of ethylhexyl stearate, and about 0.04% by weight of tridecyl alcohol polyether-6.
[0150] 56. Use of the composition as described in any of the foregoing embodiments for the manufacture of a medicament for treating dermatitis.
[0151] Numbered Examples - Group 2
[0152] 1. An aqueous antibacterial composition, said aqueous antibacterial composition comprising...
[0153] (a) Approximately 8.5%–16% glycerol by weight;
[0154] (b) about 0.45%-3% by weight of octyl glycol; and
[0155] (c) First component;
[0156] The first component is selected from the group consisting of about 0.01%-0.1% by weight of acrylates / C10-30 and about 1%-5% by weight of ethoxydiethylene glycol; and
[0157] The glycerin, caprylyl glycol, and the first ingredient together constitute more than about 13% by weight of the antibacterial composition.
[0158] 2. The aqueous antibacterial composition as described in Example 1, further comprising about 0%-1% phenoxyethanol by weight.
[0159] 3. The aqueous antibacterial composition as described in Example 1, wherein, based on the antibacterial composition, the glycerol is about 8.5%-10.7% by weight, the caprylyl glycol is about 0.6%-1.3% by weight, and the first component is ethoxyglycol and is about 2.1%-4.1% by weight.
[0160] 4. The aqueous antibacterial composition as described in Example 1, wherein the glycerol, the caprylyl glycol, and the first component constitute less than about 25% by weight of the antibacterial composition and are substantially free of alkyl glycerols and / or their alkyl esters.
[0161] 5. The aqueous antibacterial composition as described in Example 1, wherein the glycerol, the caprylyl glycol, and the first component constitute less than about 25% by weight of the antibacterial composition and are substantially free of ethylhexylglycerol.
[0162] 6. The aqueous antibacterial composition as described in Example 1, further comprising one or more compounds selected from the group consisting of panthenol, sodium polyacrylate, phenoxyethanol, ethylhexyl stearate, and tridecyl alcohol polyether-6.
[0163] 7. The aqueous antibacterial composition as described in Example 6, wherein, based on the antibacterial composition,
[0164] The panthenol is approximately 0.1% to 1% by weight;
[0165] The sodium polyacrylate is approximately 0.1% to 0.5% by weight;
[0166] The phenoxyethanol is about 0% to 1% by weight;
[0167] The ethylhexyl stearate is approximately 0% to 1% by weight; and
[0168] The tridecyl alcohol polyether-6 is approximately 0% to 1% by weight.
[0169] 8. The aqueous antibacterial composition as described in Example 1, wherein the glycerol, the caprylyl glycol, and the first component constitute less than about 25% by weight of the antibacterial composition and are substantially free of phenoxyethanol.
[0170] 9. The aqueous antibacterial composition as described in Example 8, further comprising one or more compounds selected from the group consisting of panthenol, sodium polyacrylate, ethylhexyl stearate, tridecyl alcohol polyether-6, ethylhexylglycerin, and 1,2-hexanediol.
[0171] 10. The aqueous antibacterial composition as described in Example 9, wherein, based on the antibacterial composition,
[0172] The panthenol is approximately 0.1% to 1% by weight;
[0173] The sodium polyacrylate is approximately 0.1% to 0.5% by weight;
[0174] The ethylhexyl stearate is approximately 0% to 1% by weight; and
[0175] The tridecyl alcohol polyether-6 is approximately 0% to 1% by weight.
[0176] 11. The aqueous antibacterial composition as described in any of the foregoing embodiments, wherein the composition is substantially free of sodium polyacrylate.
[0177] 12. The aqueous antibacterial composition as described in any of the foregoing embodiments, wherein the composition is substantially free of simple alcohols.
[0178] 13. The aqueous antibacterial composition as described in any of the foregoing embodiments, wherein the composition further comprises about 0.01%-0.1% of acrylate / C10-30.
[0179] 14. The aqueous antibacterial composition as described in any of the foregoing embodiments, wherein the composition further comprises about 0%-2% ethylhexylglycerin.
[0180] 15. The aqueous antibacterial composition as described in any of the foregoing embodiments, wherein the composition further comprises about 0.1% to 1% carbomer.
[0181] 16. The aqueous antibacterial composition as described in any of the foregoing embodiments, wherein the composition further comprises about 1% to 5% of 1,2-hexanediol.
[0182] 17. The aqueous antibacterial composition as described in any of the foregoing embodiments, wherein the composition further comprises one or more of the following: sodium dodecylbenzenesulfonate, sodium citrate, silver sulfate, and silver.
[0183] 18. The aqueous antibacterial composition as described in any of the foregoing embodiments, wherein the composition further comprises about 0%-5% benzyl alcohol.
[0184] 19. The aqueous antibacterial composition as described in any of the foregoing embodiments further comprises finely ground oat kernels (Avenasativa).
[0185] 20. The aqueous antibacterial composition as described in any of the foregoing embodiments, wherein the composition has the same or higher biocidal efficacy and durable bacterial inhibition compared to 75% isopropanol.
[0186] 21. The aqueous antibacterial composition as described in any of the preceding embodiments, wherein the composition is capable of exhibiting microbial killing effect greater than 4 log10 within 5 minutes.
[0187] 22. The aqueous antibacterial composition as described in any of the foregoing embodiments, wherein the composition is capable of exhibiting a virus-killing effect of greater than 6 log10 within 30 seconds or 1 minute.
[0188] 23. The aqueous antibacterial composition as described in any of the foregoing embodiments, wherein the composition effectively inhibits COVID-19 within 5 minutes.
[0189] 24. The aqueous antibacterial composition as described in any of the foregoing embodiments, wherein the composition is substantially non-evaporating.
[0190] 25. The aqueous antibacterial composition as described in any of the foregoing embodiments, wherein the composition remains on the surface to which it is applied for at least 1 minute or at least 5 minutes.
[0191] 26. The aqueous antimicrobial composition as described in Example 25, wherein the microorganism is bacteria, fungi, yeast, mold, virus, or a combination thereof.
[0192] 27. The aqueous antimicrobial composition as described in Example 25, wherein the microorganism is a virus.
[0193] 28. The aqueous antibacterial composition as described in Example 27, wherein the virus is H3N2 influenza A virus.
[0194] 29. The aqueous antimicrobial composition as described in Example 27, wherein the virus is a human coronavirus.
[0195] 30. The aqueous antimicrobial composition as described in Example 29, wherein the human coronavirus is strain 229E or COVID-19.
[0196] 31. The aqueous antimicrobial composition as described in Example 26, wherein the microorganism is one or more of Escherichia coli, Staphylococcus aureus, Candida albicans, H3N2 influenza A virus, and human coronavirus.
[0197] 32. A skin or hand sanitizer comprising an aqueous antibacterial composition as described in any of the foregoing embodiments.
[0198] 33. An aqueous antibacterial surface coating comprising an aqueous antibacterial composition as described in any of the foregoing embodiments.
[0199] 34. A woven or nonwoven wipe, sponge, or paper towel comprising an aqueous antibacterial composition as described in any of the foregoing embodiments.
[0200] 35. An aqueous antibacterial composition, said aqueous antibacterial composition comprising
[0201] Approximately 8%-20% polyols by weight;
[0202] About 1%-5% by weight of diols and / or about 0%-5% by weight of aromatic alcohols;
[0203] The total amount of the polyol, the diol, and the aromatic alcohol is about 13%-25% by weight of the composition; and
[0204] The composition is substantially free of alkylglycerols and their alkyl esters, and substantially free of simple alcohols.
[0205] 36. The aqueous antibacterial composition as described in Example 35, wherein the polyol is about 8.5%-16% glycerol by weight and about 0.45%-3% caprylyl glycol by weight.
[0206] 37. The aqueous antibacterial composition as described in Example 35, wherein the diol is about 2.06%-4.12% ethoxydiethylene glycol.
[0207] 38. The aqueous antibacterial composition as described in Example 35, wherein the aromatic alcohol is one or more of phenoxyethanol, benzyl alcohol, and phenethyl alcohol.
[0208] 39. The aqueous antibacterial composition as described in Example 35, wherein the polyol is about 1%-2% 1,2-hexanediol.
[0209] 40. The aqueous antibacterial composition as described in Example 35, further comprising silver and / or silver ions.
[0210] 41. Use of the aqueous antibacterial composition as described in any of the foregoing embodiments in the manufacture of disinfectants.
[0211] 42. An aqueous non-alcoholic disinfectant, said aqueous non-alcoholic disinfectant comprising...
[0212] Approximately 8.5%-16% glycerin by weight;
[0213] Approximately 0.45%-3% by weight of octyl glycol; and
[0214] First component;
[0215] The first component is selected from the group consisting of about 0.01%-0.1% by weight of acrylates / C10-30 and about 1%-5% by weight of ethoxydiethylene glycol; and
[0216] The total amount of the glycerin, the caprylyl glycol, and the first component is approximately 13%-25% by weight of the disinfectant.
[0217] 43. The aqueous non-alcoholic disinfectant as described in Example 42, wherein the disinfectant further comprises one or more compounds selected from the group consisting of: about 0%-1% phenoxyethanol, about 0.1%-1% panthenol, about 0%-0.5% sodium polyacrylate, about 0%-1% ethylhexyl stearate, about 0%-1% tridecyl alcohol polyether-6, and about 0.1%-1% carbomer.
[0218] 44. The aqueous non-alcoholic disinfectant as described in Example 42, wherein the disinfectant is substantially free of alkyl glycerols and / or their alkyl esters.
[0219] 45. The aqueous non-alcoholic disinfectant as described in Example 42, wherein the disinfectant is substantially free of ethylhexylglycerin.
[0220] 46. The aqueous non-alcoholic disinfectant as described in Example 42, wherein...
[0221] The first component is acrylate / C10-30, and the sum of glycerol, the caprylyl glycol and the acrylate / C10-30 is about 15% by weight.
[0222] 47. The aqueous non-alcoholic disinfectant as described in Example 42, further comprising about 0.3% panthenol, about 0.5% phenoxyethanol, and about 0.8% carbomer by weight.
[0223] 48. The aqueous non-alcoholic disinfectant as described in Example 42, further comprising about 0.3% panthenol, about 0.4% sodium polyacrylate, about 0.2% ethylhexyl stearate, about 0.07% tridecyl alcohol polyether-6, and about 0.1% carbomer by weight.
[0224] 49. The aqueous non-alcoholic disinfectant as described in Example 42, wherein
[0225] The first component is ethoxydiethylene glycol, and the total of glycerol, octyl glycol and ethoxydiethylene glycol is about 19% by weight.
[0226] 50. The aqueous non-alcoholic disinfectant as described in Example 42, further comprising about 0.5% by weight of phenoxyethanol, about 0.3% by weight of panthenol, about 0.2% by weight of sodium polyacrylate, about 0.09% by weight of ethylhexyl stearate, about 0.03% by weight of tridecyl alcohol polyether-6, and about 0.9% by weight of ethylhexylglycerin.
[0227] 51. The aqueous non-alcoholic disinfectant as described in Example 42, further comprising about 0.3% panthenol by weight, about 0.2% sodium polyacrylate by weight, about 0.11% ethylhexyl stearate by weight, about 0.04% tridecyl alcohol polyether-6 by weight, about 0.9% ethylhexylglycerin by weight, and about 1.5% 1,2-hexanediol by weight.
[0228] 52. The aqueous non-alcoholic disinfectant as described in Example 42, wherein...
[0229] The first component is ethoxydiethylene glycol, and the total amount of the glycerol, the caprylyl glycol and the ethoxydiethylene glycol is about 16.4% by weight.
[0230] 53. The aqueous non-alcoholic disinfectant as described in Example 52 further comprises about 0.5% by weight of phenoxyethanol, about 0.3% by weight of panthenol, about 0.3% by weight of sodium polyacrylate, about 0.09% by weight of ethylhexyl stearate, and about 0.03% by weight of tridecyl alcohol polyether-6.
[0231] 54. The aqueous non-alcoholic disinfectant as described in Example 53 further comprises about 0.005% sodium dodecylbenzenesulfonate, about 0.0006% sodium citrate, about 0.00015% silver sulfate, and about 0.00015% silver by weight.
[0232] 55. The aqueous non-alcoholic disinfectant as described in Example 54, further comprising about 1% benzyl alcohol by weight.
[0233] 56. The aqueous non-alcoholic disinfectant as described in Example 42, wherein...
[0234] The first component is ethoxydiethylene glycol, and the total amount of the glycerol, the caprylyl glycol and the ethoxydiethylene glycol is about 20.8% by weight.
[0235] 57. The aqueous non-alcoholic disinfectant as described in Example 56 further comprises about 0.5% by weight of phenoxyethanol, about 0.3% by weight of panthenol, about 0.2% by weight of sodium polyacrylate, about 0.11% by weight of ethylhexyl stearate, and about 0.04% by weight of tridecyl alcohol polyether-6.
[0236] 58. The aqueous non-alcoholic disinfectant as described in Example 42, wherein...
[0237] The first component is ethoxydiethylene glycol, and the total amount of the glycerol, the caprylyl glycol and the ethoxydiethylene glycol is about 17.4%-19.0% by weight.
[0238] 59. The aqueous non-alcoholic disinfectant as described in Example 58, further comprising one or more compounds selected from the group consisting of panthenol, sodium polyacrylate, ethylhexyl stearate, tridecyl alcohol polyether-6, ethylhexylglycerin, and 1,2-hexanediol.
[0239] 60. The aqueous antibacterial composition as described in Example 59, wherein, based on the antibacterial composition,
[0240] The panthenol is approximately 0.1% to 1% by weight;
[0241] The sodium polyacrylate is approximately 0.1% to 0.5% by weight;
[0242] The ethylhexyl stearate is about 0% to 1% by weight;
[0243] The tridecyl alcohol polyether-6 is about 0% to 1% by weight;
[0244] The ethylhexylglycerin is approximately 0% to 2% by weight; and
[0245] The 1,2-hexanediol is approximately 1% to 5% by weight.
[0246] 61. Use of the composition or disinfectant as described in any of the foregoing embodiments in the manufacture of a medicament for treating skin conditions (e.g., dermatitis).
[0247] 62. A method for alleviating or treating at least one skin condition in a subject in need, the method comprising:
[0248] The subject is given a therapeutic or preventative amount of the composition or disinfectant as described in any of the foregoing embodiments to treat the skin condition.
[0249] 63. The method as described in Example 62, wherein the skin condition is dermatitis.
[0250] 64. The method as described in Example 62, wherein the skin condition is selected from the group consisting of eczematous vesicles, dry skin, thickened skin, thinned skin, cracked skin, peeling skin, skin inflammation, pruritus, sweating disorder eczema, irritant contact dermatitis, skin allergy to alcohol, peeling skin, cracked skin, stiff skin, atopic dermatitis, irritant contact dermatitis, and erythema.
[0251] 65. The method as described in Example 62, wherein the composition or disinfectant is applied topically.
[0252] 66. A method for killing microorganisms within 30 seconds to 1 minute by contacting them with a composition or disinfectant as described in any of the foregoing embodiments.
[0253] 67. The method as described in Example 66, wherein the microorganism is one or more of Escherichia coli, Staphylococcus aureus, Candida albicans, H3N2 influenza A virus, or human coronavirus (e.g., COVID-19).
[0254] Example
[0255] The following examples are not intended to limit the scope of the invention, but are merely exemplary in nature.
[0256] Example 1
[0257] Preparations and methods
[0258]
[0259]
[0260] The following compositions are formulated as described in Table 1.1 (proportions are in weight percentages (%)). Table 1.1. Exemplary compositions according to the present invention.
[0261] In some exemplary embodiments, the composition contains glycerol, caprylyl glycol, and a first component, wherein the first component is an acrylate / C10-30 and / or ethoxydiethylene glycol. Glycerol, caprylyl glycol, and the first component together form a first component. In some exemplary embodiments and as seen in compositions A and G above, the composition may contain about 14.47% by weight of glycerol, about 0.45% by weight of caprylyl glycol, about 0.03% by weight of an acrylate / C10-30, and water to 100%. In these embodiments, the composition does not contain ethoxydiethylene glycol. In another exemplary embodiment and as seen in composition A, the formulation may further contain about 0.3% by weight of panthenol, about 0.5% by weight of phenoxyethanol, and about 0.75% by weight of carbomer. In this exemplary embodiment, the composition does not contain sodium polyacrylate. In another exemplary embodiment and as seen in composition G, the composition may further contain about 0.3% by weight of panthenol, about 0.414% by weight of sodium polyacrylate, about 0.5% by weight of phenoxyethanol, about 0.207% by weight of ethylhexyl stearate, about 0.069% by weight of tridecyl alcohol polyether-6 and about 0.12% by weight of carbomer.
[0262] In some exemplary embodiments, and as seen in compositions B and D above, the composition may contain about 13.01% glycerol by weight, about 2.947% octyl glycol by weight, and about 3.09% ethoxydiethylene glycol by weight, and water to a total of 100%. In another exemplary embodiment, and as seen in composition B, the composition may further contain about 0.3% panthenol by weight, about 0.18% sodium polyacrylate by weight, about 0.5% phenoxyethanol by weight, about 0.09% ethylhexyl stearate by weight, about 0.03% tridecyl alcohol polyether-6 by weight, and about 0.858% ethylhexylglycerin by weight. In another exemplary embodiment, and as seen in composition D, the composition may further contain about 0.3% by weight panthenol, about 0.21% by weight sodium polyacrylate, about 0.105% by weight ethylhexyl stearate, about 0.035% by weight tridecyl alcohol polyether-6, about 0.858% by weight ethylhexylglycerin, and about 1.5% by weight 1,2-hexanediol. In this exemplary embodiment, the composition is free of phenoxyethanol.
[0263] In some exemplary embodiments and as seen in composition C above, the composition may contain about 15.386% glycerol by weight, about 1.26% octyl glycol by weight, and about 4.12% ethoxydiethylene glycol by weight, and make up to 100% water. In other exemplary embodiments and as seen in composition C, the composition may further contain about 0.282% panthenol by weight, about 0.226% sodium polyacrylate by weight, about 0.471% phenoxyethanol by weight, about 0.113% ethylhexyl stearate by weight, about 0.038% tridecyl alcohol polyether-6 by weight, and about 0.113% ethylhexylglycerin by weight.
[0264] In some exemplary embodiments, and as seen in compositions E and F above, the composition may contain about 12.5% glycerol by weight, about 0.9% octyl glycol by weight, and about 3% ethoxydiethylene glycol by weight, and make up to 100% water. In other exemplary embodiments, the composition may further contain about 0.3% panthenol by weight, about 0.33% sodium polyacrylate by weight, about 0.5% phenoxyethanol by weight, about 0.09% ethylhexyl stearate by weight, and about 0.03% tridecyl alcohol polyether-6 by weight. In other exemplary embodiments, and as seen in composition E, the composition may further contain about 0.005% sodium dodecylbenzenesulfonate by weight, about 0.0006% sodium citrate by weight, about 0.00015% silver sulfate by weight, and about 0.00015% silver. In yet another exemplary embodiment and as seen in composition F, the composition may further contain about 1% benzyl alcohol by weight.
[0265] Method for preparing exemplary formulations
[0266] The components and percentages used to prepare the exemplary compositions are listed in Table 1. In some exemplary embodiments, all components may be mixed together in water with moderate mechanical stirring until homogeneous. If desired, the mixture may be stirred at a suitable high temperature (e.g., 30°C–60°C). The pH of the final composition may be adjusted to approximately 5–7 using a suitable pH adjuster (e.g., sodium hydroxide or sodium citrate).
[0267] In other exemplary embodiments, a gelling agent (such as carbomer) and / or a thickener (such as sodium polyacrylate or acrylate / C10-30) may be heated in an appropriate amount of water at a suitable high temperature (e.g., about 60°C) with slow mechanical stirring to obtain phase 1. The remaining components may then be dissolved in an appropriate amount of water with stirring at another suitable temperature (e.g., about 40°C) to obtain phase 2. In another exemplary embodiment, if certain components are temperature-sensitive, these components may be prepared individually as phase 3 (or more phases) at a suitable temperature (e.g., ambient temperature). To obtain the final product, phases 1 and 2 are mixed together with moderate stirring. Phase 3 is added when the gel temperature reaches a suitable temperature (e.g., ambient temperature). The pH may be adjusted to approximately 5-7 using a pH adjuster (e.g., sodium hydroxide or sodium citrate).
[0268] Example 2
[0269] Methods and Materials
[0270] Antibacterial and antifungal efficacy test
[0271] The bactericidal and fungicidal efficacy of the exemplary compositions was tested using the suspension quantitative bactericidal test and the fungicidal test method in accordance with Sections 2.1.1.7.4 and 2.1.1.7.9 of the Disinfection Technical Standard (Ministry of Health of the People's Republic of China, 2002), which is incorporated herein by reference.
[0272] Suspended quantitative killing test 2.1.1.7.4 Operating procedure:
[0273] (1) First, prepare the disinfectant solution according to the requirements of the product manual. Unless otherwise specified, use sterile hard water to prepare the solution, and the concentration of the preparation should be 1.25 times the concentration to be tested (for example, if the concentration of the disinfectant to be evaluated is 200 mg / L, the preparation should be prepared to be 250 mg / L). Place it in a water bath at 20℃±1℃ for later use.
[0274] (2) Prepare a suspension of the experimental bacteria to be tested, with a concentration of 1×10⁻⁶. 8 cfu / ml up to 5×10 8 cfu / ml.
[0275] (3) First, add 0.5 ml of the test bacterial suspension, then add 0.5 ml of the organic interfering substance, mix thoroughly, and incubate the mixture in a water bath at 20℃±1℃ for 5 min. Then, use a sterile pipette to transfer 4.0 ml of the prepared disinfectant solution to the mixture, mix the mixture quickly, and record the time immediately.
[0276] (4) Allow the test bacteria to react with the disinfectant until each predetermined time, then transfer 0.5 ml of the mixed solution of test bacteria and disinfectant and mix it with 4.5 ml of sterilized neutralizer and mix the solution thoroughly.
[0277] (5) After adding the neutralizing agent to the mixture of test bacteria and disinfectant in each tube for 10 minutes, aspirate 1.0 ml of the sample liquid and determine the viable count according to the viable culture plate counting method. Inoculate two agar plates for each sample liquid. If the number of colonies growing on the plate is too high, a series of 10-fold dilutions can be performed to allow for viable culture counting.
[0278] (6) At the same time, a positive control was prepared by using a diluent instead of a disinfectant.
[0279] (7) Incubate all test samples in a 37°C incubator and observe the final results after 48 hours of bacterial culture. For bacterial spores, the test samples need to be incubated for 72 hours to observe the final results.
[0280] (8) Repeat the test three times and calculate the viable bacterial concentration (cfu / ml) for each group. Convert the results to logarithmic values (N), and then calculate the kill logarithm using the following formula: Kill Logarithm (KL) = Logarithm of the average viable bacterial concentration in the control group (No) - Logarithm of the viable bacterial concentration in the test group (Nx). When calculating the kill logarithm, round to two decimal places. If the average number of colonies produced after disinfection in the disinfection test group is less than or equal to 1, then the kill logarithm is greater than or equal to the logarithm of the average viable bacterial concentration in the control group before the test.
[0281] Fungal Killing Test 2.1.1.9 Operating Procedures:
[0282] This test is to verify the dosage of disinfectant in suspension or on a carrier required to kill fungal cultures or spores in the laboratory, in order to demonstrate an effective disinfectant dosage for fungi and their spores.
[0283] Test equipment / materials
[0284] (1) Malt extract agar (MEA).
[0285] (2) Sandburg agar medium.
[0286] (3) Preparation of test microorganisms and their suspensions or mycelial balls
[0287] Candida albicans ATCC 10231 and / or Aspergillus niger ATCC 16404 or spore suspensions and their mycelial balls.
[0288] In addition, depending on the specific use and special needs of the disinfectant, other fungal or spore suspensions and mycelial balls can be selected.
[0289] (4) Neutralizing agent.
[0290] (5) Phosphate buffer (PBS, 0.03 mol / L, pH 7.2).
[0291] (6) Hard water used for diluting disinfectants.
[0292] (7) Organic interfering substances.
[0293] (8) Graduated pipettes (0.1ml, 1.0ml, 5.0ml).
[0294] (9) Constant temperature water bath.
[0295] (10) Spraying device (for spray disinfection testing).
[0296] (11) Electric mixer.
[0297] (12) Timing device.
[0298] 2.1.1.9.3 Preparation of fungal suspension
[0299] (1) Preparation of Candida albicans suspension
[0300] 1) Take a lyophilized bacterial culture tube and aseptically open it. Use a capillary pipette to transfer an appropriate amount of Saburg liquid medium into the tube. Disperse the culture by aspirating several times. Prepare a test tube containing 5.0 ml to 10.0 ml of Saburg liquid medium and add a few drops of the bacterial suspension. Incubate the culture at 37°C for 18 to 24 hours. Use an inoculation loop to take a suspension of the first-generation culture and streak it onto Saburg agar. Incubate the agar at 37°C for 18 to 24 hours. Select typical colonies from the second-generation culture and inoculate them onto a Saburg agar slant. Incubate the agar at 37°C for 18 to 24 hours to form the third-generation culture. After sealing, store the culture at 4°C and do not use it for more than 6 weeks.
[0301] 2) During the experiment, third-generation cultures were continuously passaged on Saburg agar slants using the same method as for preparing the third generation. Fresh fifth- or sixth-generation Saburg agar slants were used to culture fresh cultures (18-24 hours). Using a 5.0 ml pipette, 3.0 ml-5.0 ml of diluent was transferred to the slants, and the culture was washed repeatedly by up-and-down pipetting of the diluent. Subsequently, the wash solution was transferred to another sterile tube and mixed for 20 seconds or by gently tapping the tube 80 times on the palm of the hand to ensure a homogeneous Candida albicans suspension.
[0302] 3) In the suspension sterilization test, the fungal count in the experimental suspension was 1 × 10⁻⁶. 7 cfu / ml up to 5×10 7 cfu / ml.
[0303] 4) Store the fungal suspension in a refrigerator at 4°C for use within one day. Overnight cultures will not be used.
[0304] 5) When contamination is suspected, identification should be performed using methods such as colony morphology, Gram staining, and biochemical tests. Colony morphology can be observed directly under a microscope. After smearing, the morphology of the fungi can be observed directly under a high-powered microscope, or it can be stained and observed using the ink shade method (mixing the culture with black ink on a glass slide and spreading it into a film).
[0305] (2) Preparation of Aspergillus niger ATCC 16404 suspension or mycelial balls.
[0306] 1) Take a lyophilized culture tube and aseptically open it. Transfer a small amount of malt extract broth medium to the tube and add it to the fungus. Gently transfer the culture into the tube to disperse the culture sediment. Add a small amount of sediment suspension to a test tube containing 5.0 ml of malt extract broth medium and incubate at 30℃±1℃ for 42-48 hours. Inoculate the first-generation culture onto MEA agar and incubate at 30℃±1℃ for 42-48 hours. Select typical colonies from the culture plate and inoculate them onto malt extract nutrient agar slant medium. Incubate the slant culture at 30℃±1℃ for 42-48 hours; this becomes the third-generation culture. After sealing, store the culture at 4℃ and use within 9 weeks.
[0307] 2) During the testing period, third-generation slant cultures were inoculated onto malt extract agar slant and incubated at 30°C for 48 hours. The cultures on the slant were washed with 3.0 to 5.0 ml of malt extract broth and inoculated into Roche bottles, which were then agitated to spread the cultures over the surface of the MEA medium. Excess broth was then aspirated, and the Roche bottles were incubated at 30°C ± 1°C for 7–9 days.
[0308] 3) Add 5.0 ml to 10.0 ml of 0.05% (v / v) Tween 80 saline solution to the Roche flask culture, and scrape off Aspergillus niger spores and wash them in the solution. Transfer the spore suspension to an Erlenmeyer flask with glass beads and gently shake for 1 minute. Filter to remove mycelium. After filtration, observe the suspension under a microscope (400x) to check for the presence of mycelium. If mycelium is present, centrifuge the suspension at 5000 rpm to 6000 rpm for 20 minutes. Observe the suspension again under a microscope (400x) to see if mycelium is still present. If mycelium is still present, the suspension must be centrifuged again.
[0309] 4) Aspergillus niger fungal suspensions should be stored at 2℃-8℃ but not for more than 2 days. Before use, mix the suspension thoroughly and observe under a microscope (400x) to see if spores are germinating. If spores are germinating, discard the suspension.
[0310] 5) When using, it can be appropriately diluted with a diluent. During the suspension test, the spore content of the experimental fungal suspension was 1×10⁻⁶. 7 cfu / ml -5×10 7 cfu / ml.
[0311] 6) The staining method for preparing stained samples is the drop staining method. Add 10 μl of fungal suspension to each slide. After staining the fungus, dry it in an incubator at 37°C (approximately 30 min), or dry it at room temperature before use.
[0312] 7) The number of recovered fungi should reach 5 × 10⁻⁶. 5 CFU / tablets - 5 x 10 6 The CFU / tablet can be determined based on testing requirements.
[0313] 2.1.1.9.4 Test Group
[0314] The tests were divided into the following groups:
[0315] (1) The test group selected the disinfectant concentration and contact time according to the provisions of 2.1.1.7.3 to test the killing effect on the tested strains.
[0316] (2) For the positive control group, hard water was used instead of the disinfectant solution, and the test was conducted according to the procedure specified in 2.1.1.7.3. The results represent the initial concentration of the test strain contained in the test system, and the logarithm of the disinfection factor of the test strain was calculated.
[0317] (3) Negative control group, to check whether the relevant test solutions and culture media used in the same experiment were contaminated.
[0318] 2.1.1.9.5 Test Program
[0319] The culture media to be used are Saburg dextrose agar for Candida albicans and malt extract agar (MEA) for Aspergillus niger. Please refer to 2.1.1.7 for the operating procedures.
[0320] When counting viable bacteria, *Candida albicans* was incubated at 37°C for 48 hours to observe the final results. For *Aspergillus niger*, it was incubated at 30°C for 72 hours to observe the final results.
[0321] 2.1.1.9.6 Evaluation Requirements
[0322] (1) For product supervision and inspection, repeat the test three times according to the concentration and action time specified in the product instruction manual.
[0323] For each test of Candida albicans and Aspergillus niger with a logarithmic kill value ≥4.00, if the logarithmic value is ≥3.00, the product can be deemed qualified for disinfection of fungal contaminants.
[0324] (2) For sanitary permit testing used for product declaration, the test shall be conducted according to the concentration and three action times specified in the product instruction manual, and the test shall be repeated three times. The suspension quantitative killing test shall be conducted using the concentration and the minimum action time specified in the product instruction manual, and the minimum action time shall be 1.5 times. The log value of each test shall be ≥4.00. When the concentration is 0.5 times the minimum action time, the log value of killing is allowed to be less than 4.00. Then the effective dose of the product used in the laboratory to disinfect the fungal contaminant being tested can be determined.
[0325] For quantitative sterilization tests using a carrier soaked in the product to evaluate sterilization effectiveness, the effective dose of the product used in the laboratory to disinfect the tested fungal contaminant can be determined by using the concentration and minimum contact time according to the product specifications, and by ensuring that the log kill count is ≥3.00 for each test when using 1.5 times the minimum contact time, and that the log kill count is less than 3.00 when using 0.5 times the specified concentration and minimum contact time.
[0326] Example 3
[0327] Antiviral efficacy test
[0328] The antiviral efficacy of the exemplary composition was tested using identification tests of physical removal methods for residual disinfectants, in accordance with Sections 2.1.1.10.6 and 2.1.110.7 of the Disinfection Technical Standard (Ministry of Health of the People's Republic of China, 2002), which is incorporated herein by reference.
[0329] Identification Test for Physical Removal Methods of Residual Disinfectants 2.1.1.10.6 Operating Procedures:
[0330] In virus inactivation tests, physical removal methods include dilution, followed by adsorption column method, molecular sieve column method, and carrier washing method.
[0331] (1) Grouping
[0332] 1) Disinfectant + virus suspension → inoculate culture
[0333] The study aimed to observe whether the tested disinfectant had an inactivating or inhibitory effect on the virus, and whether it affected normal cell growth.
[0334] 2)(Disinfectant + Virus Suspension) + Drug Removal Treatment → Inoculation Culture
[0335] Observe whether the virus can resume cell infection after the removal of residual drugs.
[0336] 3) Virus suspension + drug removal treatment → inoculation culture
[0337] Observe whether the drug removal treatment has any effect on the viral titer.
[0338] 4) Virus suspension → Inoculation culture
[0339] Observe whether the virus grows normally, and use this result as a positive control.
[0340] 5) Cell cultures not inoculated with the virus
[0341] Observe whether the cells are growing normally.
[0342] (2) Suspension Quantitative Operation Procedure
[0343] Group 1. Aspirate 0.9 ml of the antidote to be tested into a test tube and incubate in a water bath at 20°C ± 1°C for 5 minutes. Then add 0.1 ml of virus suspension and mix thoroughly. After the reaction has continued for the time specified in the test for virus inactivation, aspirate the final sample solution (or a sample solution serially diluted with an appropriate virus-free diluent) according to the specified test volume and perform subsequent virus titer determination.
[0344] 2) Group 2. Aspirate 0.9 ml of the disinfectant to be tested into a test tube and incubate in a water bath at 20℃±1℃ for 5 minutes. Then add 0.1 ml of virus suspension and mix thoroughly. After the specified duration of action, treat the solution to remove the disinfectant and aspirate the final sample (or a sample serially diluted with an appropriate virus-free diluent) according to the specified test volume for subsequent virus titer determination.
[0345] 3) Group 3. Aspirate 0.1 ml of the virus suspension and add 0.9 ml of cell culture medium for drug removal treatment. Aspirate the final sample (or a sample serially diluted with an appropriate virus-free diluent) according to the amount specified in the test, and then proceed with the subsequent virus titer determination.
[0346] 4) Group 4. Aspirate 0.1 ml of the virus suspension and add 0.9 ml of cell maintenance medium without adding disinfectant or performing any drug removal treatment. Aspirate the specified amount of virus suspension (or a serially diluted sample using an appropriate virus-free diluent) according to the test specifications, and then proceed with the subsequent virus titer determination.
[0347] 5) Group 5. For cell tubes that were not inoculated with the virus, add complete cell culture medium for culturing.
[0348] (3) Evaluation Requirements
[0349] If the test results meet all of the following conditions, the tested physical removal method can be considered qualified:
[0350] 1) Group 1 had no virus tested or only a small amount of growth.
[0351] 2) Group 2 had much more test virus growth than Group 1, but significantly less test virus growth than Groups 3 to 5.
[0352] 3) The virus growth in the third, fourth and fifth (groups) tests was similar.
[0353] 4) Obtain a pass rating for three consecutive tests.
[0354] 5) Viral vectors can be used, and experiments can be conducted according to the same principles and operating procedures, with the same judgment criteria.
[0355] Poliovirus inactivation test 2.1.1.10.7 Operating procedure:
[0356] (1) Purpose
[0357] To determine the dosage of disinfectant required to inactivate poliovirus (PV) in order to verify the effective dosage for viral contaminants.
[0358] (2) Experimental Principle
[0359] The amount of poliomyelitis in samples before and after disinfectant treatment (or in experimental and control groups) was determined using a cell infection method. Cellular disease was used as an indicator to determine the viral infection titer in each group, and the inactivation rate of the disinfectant against poliomyelitis was calculated.
[0360] (3) Test Group
[0361] 1) Test group.
[0362] Based on the estimated killing or inactivation dose of disinfectant for other microorganisms, set appropriate concentration and action time groups (no less than 1 concentration and 3 action times), and the action time should be designed to be no less than 30 seconds.
[0363] 2) Positive control group.
[0364] Using deionized water instead of disinfectant, polio suspension was added according to the test group's prescribed steps for testing and culture, and the growth of polio was observed.
[0365] 3) Negative control group.
[0366] A complete culture medium free of poliomyelitis was used as a negative control to observe whether the culture medium was contaminated and whether the cells grew well.
[0367] (4) Procedure for quantitative inactivation test of polio suspension
[0368] 1) Remove the frozen test host cells from liquid nitrogen and thaw them rapidly in warm water at 37°C. Wash them twice with cell maintenance medium before transferring them to a culture flask containing 10 ml of complete culture medium. Observe cell growth daily, and when the cells have grown into a monolayer, they can be used for sterilization testing.
[0369] 2) Remove the cryopreserved poliovirus-1 strain, thaw it in a 37°C water bath, dilute it 10-fold with cell maintenance medium, and then inoculate it into a cell culture flask containing a monolayer of cells. Incubate the flask at 37°C to allow the virus to adsorb and grow with the cells. Observe the disease daily and harvest the virus when 3 / 4 of the cells are damaged. Upon harvesting, remove the culture medium, disrupt the host cells by sonication or repeated freeze-thaw cycles, and centrifuge as quickly as possible. Aliquot 1.0 ml of the virus-containing supernatant into sterile centrifuge tubes (1.5 ml each) and store at -80°C for later use.
[0370] 3) Take the disinfectant to be tested, dilute it with sterile hard water to the required concentration of 1.25 times, and incubate it in a water bath at 20℃±1℃ for use.
[0371] 4) Mix 100 μl of organic interfering substance with 100 μl of virus stock solution and allow the mixture to react in a water bath at 20℃±1℃ for 5 minutes. Add 0.8 ml of the disinfectant to be tested, mix immediately, and record the time. After the specified time period, immediately remove 0.1 ml of the mixture and add it to the neutralizing agent, mixing thoroughly; or treat with an approved drug removal method.
[0372] 5) In the positive (virus) control group test, sterile deionized water was used instead of the disinfectant to be tested.
[0373] 6) Determine the viral titer for each group individually, which can be done using the endpoint dilution method or the plaque method.
[0374] 7) Repeat the test 3 times.
[0375] 8) Endpoint dilution method operation steps:
[0376] First, the titrated samples were serially diluted 10-fold using cell maintenance medium. Then, the residual virus amount from each dilution was titrated onto a 96-well plate, with four wells prepared for each dilution (each well should be covered with a monolayer of host cells), and incubated at 37°C for 1–2 hours to ensure all residual virus was adsorbed onto the cells. The plate was removed and the cell maintenance medium was replaced. Incubation was continued in a CO2 incubator (37°C, 5% CO2) for further culture. Cell damage was observed daily under a microscope for 3 days. Cell damage was observed and recorded well by well. The viral infection titer calculated using the endpoint dilution method is expressed as half the cell infection dose (TCID50).
[0377] 9) Operating procedures for the etching method:
[0378] First, the titrated sample is serially diluted 10-fold using cell maintenance medium, then inoculated into cell culture flasks, and the residual virus amount in each dilution is titrated. Before inoculation, the culture medium in the densely grown monolayer of cells is decanted, 1 ml of the sample to be tested is added, and the flask is incubated at 37°C for 1-2 hours for adsorption. The sample solution is decanted, and 3 ml of cell maintenance medium containing 0.8% agar is added. After cooling, the cell flask is inverted and incubated at 37°C for 48-72 hours. Then, 2 ml of formaldehyde solution is added to each flask for fixation for a few minutes, rinsed with tap water, and stained with crystal violet solution for a few minutes, followed by rinsing and counting. The circular, unstained, transparent areas in the cell flask are plaque units. The virus content per milliliter of test sample is calculated as: pfu / ml = average number of plaques on the plate × dilution factor. Note: For ease of counting, the number of viral plaques is usually controlled between 10 and 30 pfu per cell flask.
[0379] (5) Calculation of the mean inactivation log
[0380] The mean log inactivation value is calculated using the following formula: Set the mean viral infection titer (TCID50 or pfu) of the positive (virus) control group as N0, and the mean viral infection titer (TCID50 or pfu) of the test (disinfection) group as Nx. Mean log inactivation value = log N0 - log Nx
[0381] (6) Evaluation Requirements
[0382] 1) The poliovirus inactivation test can be used to evaluate the inactivation effect of chemical disinfectants on viruses on medical devices, tableware, surfaces, and skin. The virus inactivation titer should reach 4 logarithms.
[0383] 2) Under normal circumstances, an average inactivation log of ≥4.00 across three tests can be considered a qualified laboratory test for disinfection of poliovirus contaminants. Simultaneously, the logarithm of the viral titer in the positive control group should be between 5 and 7.
[0384] (7) Preventive measures
[0385] 1) Operators should have basic experience in virology experiments and try using pipettes and sterile disposable tips.
[0386] 2) In sterilization tests, a positive control should be set up each time.
[0387] 3) If a viral vector is used for testing, refer to the above-described suspension quantitative test procedure and make appropriate modifications based on virological principles before use.
[0388] Example 4
[0389] Antibacterial activity of chemical disinfectants and antimicrobial agents according to BS EN 1276:2009
[0390] Chemical disinfectants and antimicrobial agents - Quantitative suspension test (Phase 2, Step 1) for evaluating the bactericidal activity of chemical disinfectants and antimicrobial agents used in the food, industrial, household, and public sector.
[0391] Recommended dilution: undiluted
[0392] Product test concentration: 80% (w / w)
[0393] Experimental conditions
[0394] Contact time: 1 minute (for hand disinfection)
[0395] Test temperature: 20℃
[0396] Appearance: Translucent viscous liquid
[0397] Interfering substance: 0.3 g / L bovine albumin (in dirty conditions)
[0398] Inhibition method: Dilution-neutralization
[0399] Neutralizing solution: D / E neutralizing broth - double concentration (sodium thioacetate 2.0 g / L, sodium thiosulfate 12.0 g / L, sodium bisulfite 5.0 g / L, polysorbate 80 10.0 g / L, lecithin 14.0 g / L)
[0400] Incubation: 37℃, 48 hours
[0401] Agar medium: tryptic soy agar
[0402] Test strains: Escherichia coli ATCC 10536, Pseudomonas aeruginosa ATCC 15442, Staphylococcus aureus ATCC 6538, and Enterococcus hirae ATCC 10541
[0403] Example 5
[0404] Durability test
[0405] To evaluate the durability of bacterial inhibition of the exemplary composition, a durability test was performed by periodically adding a fixed amount of bacteria to the sample, and the procedure described herein is incorporated by reference.
[0406] Prepare:
[0407] Group A: Agar plates containing 0.5 mL of distilled water;
[0408] Group B: Agar plates containing 0.5 mL of 75% isopropanol (IPA);
[0409] Group C: Agar plates containing an exemplary composition tested at 0.5g.
[0410] Bacterial strains used: BOD inoculum capsules (one capsule dissolved in 500 mL of distilled water) (Interlab) contain a blend of broad-spectrum bacteria specifically designed as inoculum for biochemical oxygen demand (BOD5) testing, which is performed according to the Standard Methods of the Examination of Water and Wastewater. It is an EPA-approved BOD5 inoculum that has been used to inoculate both municipal and industrial waste for nearly 20 years.
[0411] Agar: Tryptone Soy Agar (TSA)
[0412] Incubation conditions: 48 hours at 30℃±1℃.
[0413] Test program
[0414] The agar plates of the above three sample groups were used as sample matrices for adding 0.5 ml of bacterial solution every 60 minutes under different initial conditions, namely: the bacterial addition process was in progress at times of 0, 60, 120, 180, 240, and 300 minutes.
[0415] Swab tests were performed on the matrix samples from each group every 30 minutes to test the viable bacterial count at the time interval.
[0416] Examples of samples in chronological order:
[0417] AM: Add 0.5 ml of bacterial solution at T0-10 min;
[0418] Sample A1: Wiped from AM at T0; Sample A2: Wiped from AM at T1;
[0419] AM: Add 0.5 ml of bacterial solution at T2-10 min;
[0420] Sample A3: Wiped from AM at T2; Sample A4: Wiped from AM at T3;
[0421] AM: Add 0.5 ml of bacterial solution at T4-10 min; etc. Table 2 summarizes the test plan for the durability test.
[0422]
[0423]
[0424] Table 1.2 Test plan for durability testing.
[0425] Example 6
[0426] Volatility test
[0427] To investigate the duration of the bacterial inhibitory ability of the exemplary composition, a volatility test was performed.
[0428] Prepare:
[0429] Group A: Agar plates containing 0.5 mL of distilled water;
[0430] Group B: Agar plates containing 0.5 mL of 75% isopropanol (IPA);
[0431] Group C: Agar plates containing an exemplary composition tested at 0.5g.
[0432] Bacterial strains used: BOD inoculum capsules (1 capsule dissolved in 500 mL of distilled water) (Interlabor Company)
[0433] Agar: Tryptone Soy Agar (TSA)
[0434] Incubation conditions: 48 hours at 30℃±1℃.
[0435] Test program
[0436] As defined in Table 1.3, in T x At regular intervals, 0.5 mL of bacterial solution was added to agar plate groups A, B, and C.
[0437]
[0438]
[0439] Table 1.3 Test Plan for Volatility Testing
[0440] In T 10 Then, the bacterial solution was added to all agar plates except the agar blank.
[0441] In time interval T x A swab test was performed to determine the viable bacterial count.
[0442] Example 7
[0443] Antibacterial efficacy against different materials
[0444] To test the disinfection efficacy against different materials, the exemplary composition was tested for its bacterial inhibition efficacy against different materials.
[0445] Five different materials, including plastic, leather, glass, wood, and tile, were treated with the exemplary composition to be tested. At each time interval Tx as shown in Table 1.4, a bacterial solution was added to the surface of each test material. The test area to be examined was 5 cm × 5 cm. After T2 (i.e., 3 hours), the bacterial solution was added to each area treated with the exemplary composition and waited for 10 minutes. A (positive) control was prepared by adding 0.5 ml of the bacterial solution to an agar plate without any further treatment.
[0446]
[0447]
[0448] Table 1.4 Test Plan for Disinfection Effectiveness
[0449] Perform a swab test to determine the viable bacterial count. Calculate the removal efficiency (%) using the following formula: Removal efficiency (%) = (Control viable count - Test viable count) / Control viable count × 100%
[0450] Example 8
[0451] Toxicological risk assessment
[0452] A toxicological risk assessment (TRA) is conducted based on general principles of toxicology and with reference to EU and US cosmetic regulations and standards. It reviews the product's safety for consumer health. In some exemplary embodiments, the product is intended to be applied to hands after handwashing to keep children one year of age or older in good condition.
[0453] This review was compiled using information collected from raw material suppliers and various online databases, including opinions from the European Union Scientific Committee on Consumer Safety (SCCS) and the Cosmetic Ingredient Review (CIR); for detailed references, please refer to the SGS Scientific Archive.
[0454] result
[0455] Example 9
[0456] Biocidal efficacy test results
[0457]
[0458] Table 2 shows the summarized biocidal efficacy test results of Composition A described in Example 1 using the method described in Example 2. The results show that, unexpectedly, Composition A exhibited a log kill value of ≥5.00 and a kill rate of >99.999% against Escherichia coli, Staphylococcus aureus, and Candida albicans within a 5-minute reaction time, indicating that the composition effectively kills Gram-negative and Gram-positive bacteria, as well as fungi (such as yeast), within a short action time (within 5 minutes).
[0459] Example 10
[0460] Viral efficacy test results
[0461]
[0462] Tables 3 and 4 show the summary results of the antiviral efficacy of Composition A described in Example 1 using the method described in Example 3. Based on tests conducted under the conditions specified in Example 3, Composition A unexpectedly exhibited satisfactory antiviral activity against H3N2 influenza A with reaction times of 30 seconds and 5 minutes, respectively, indicating that the composition is an effective antiviral agent with a short duration of action (within 30 seconds).
[0463] Example 11
[0464] The antibacterial activity results of composition B described in Example 1 of the method according to BS EN 1276:2009 in Example 4 are shown in Tables 5-6.
[0465]
[0466]
[0467] According to tests conducted under the conditions specified in EN 1276, composition B unexpectedly exhibited satisfactory bactericidal activity against reference strains Escherichia coli ATCC 10536, Pseudomonas aeruginosa ATCC 15442, Staphylococcus aureus ATCC 6538, and Enterococcus haematobacterium ATCC 10541 after a 1-minute contact time at 20°C under soiled conditions (0.3 g / L bovine serum albumin), indicating that the composition effectively kills bacteria under short contact time (within 1 minute).
[0468] Example 12
[0469] The antibacterial activity results of composition C described in Example 1 of the method according to BS EN 1276:2009 in Example 4 are shown in Tables 7-8.
[0470]
[0471]
[0472] According to tests conducted under the conditions specified in BS EN 1276, composition C unexpectedly met all criteria for bacterial activity (“satisfactory” scores) against reference strains Escherichia coli ATCC 10536, Pseudomonas aeruginosa ATCC 15442, Staphylococcus aureus ATCC 6538, and Enterococcus haematobacterium ATCC 10541 after a 1-minute contact time at 20°C under soiled conditions (0.3 g / L bovine serum albumin), indicating that the composition effectively kills bacteria under short contact time (within 1 minute).
[0473] Example 13
[0474] Durability test
[0475] Table 9 summarizes the durability test results of the exemplary composition B described in Example 1 using the method described in Example 5.
[0476] time water CFU / board 75% IPA CFU / board Sample composition CFU / board <![CDATA[T0(0min)]]> A1 18 B1 8 C1 1 <![CDATA[T1(30min)]]> A2 35 B2 28 C2 2 <![CDATA[T2(60min)]]> A3 46 B3 53 C3 1 <![CDATA[T3(90min)]]> A4 99 B4 89 C4 2 <![CDATA[T4(120min)]]> A5 247 B5 254 C5 1 <![CDATA[T5(150min)]]> A6 334 B6 346 C6 6 <![CDATA[T6(180min)]]> A7 Uncountable B7 Uncountable C7 6 <![CDATA[T7(210min)]]> A8 Uncountable B8 Uncountable C8 13 <![CDATA[T8(240min)]]> A9 Uncountable B9 Uncountable C9 15 <![CDATA[T9(270min)]]> A10 Uncountable B10 Uncountable C10 23 <![CDATA[T 10 (300min)]]> A11 Uncountable B11 Uncountable C11 20
[0477] Table 9 shows the durability test results of the exemplary compositions. "Uncountable" means that there are too many bacterial colonies in the agar plate to be counted, for example, more than 335 colonies per plate.
[0478] Based on tests conducted under the conditions specified in Example 5, Composition B unexpectedly exhibited excellent bactericidal activity of more than 75% IPA or water from treatment time of 0 min to 300 min, despite the fact that more bacteria were added at fixed time intervals, indicating that the exemplary composition provides good antimicrobial efficacy.
[0479] Example 14
[0480] Volatility test
[0481] Table 10 summarizes the durability test results of the exemplary composition B described in Example 1 using the method described in Example 6.
[0482] time water CFU / board 75% IPA CFU / board Sample composition CFU / board <![CDATA[T0(0min)]]> A1 60 B1 54 C1 6 <![CDATA[T1(30min)]]> A2 49 B2 62 C2 7 <![CDATA[T2(60min)]]> A3 55 B3 50 C3 5 <![CDATA[T3(90min)]]> A4 47 B4 45 C4 6 <![CDATA[T4(120min)]]> A5 50 B5 49 C5 4 <![CDATA[T5(150min)]]> A6 43 B6 55 C6 4 <![CDATA[T6(180min)]]> A7 44 B7 43 C7 3 <![CDATA[T7(210min)]]> A8 43 B8 37 C8 3 <![CDATA[T8(240min)]]> A9 29 B9 44 C9 2 <![CDATA[T9(270min)]]> A10 49 B10 49 C10 3 <![CDATA[T 10 (300min)]]> A11 44 B11 0 C11 0
[0483] Table 10. Summary Results of Durability Testing
[0484] According to tests conducted under the conditions specified in Example 6, Composition B unexpectedly maintained over 75% bactericidal activity in IPA or water for extended periods from 0 min to 300 min of treatment time.
[0485] Example 15
[0486] Antibacterial efficacy against different materials
[0487] Table 11 summarizes the durability test results of the exemplary composition B described in Example 1 using the method described in Example 7.
[0488]
[0489]
[0490] Table 11 summarizes the results of the durability test.
[0491] Based on tests conducted under the conditions specified in Example 7, Composition B exhibited surprisingly effective bactericidal activity (80%-100% bacterial removal efficiency) on various material surfaces (including plastics, leather, glass, wood, and tiles) from treatment time of 0 to 3 hours, indicating that the composition is an effective and long-lasting disinfectant for use as a surface coating on various materials.
[0492] Example 16
[0493] Toxicological Risk Assessment (TRA) Results
[0494] Consumer health risk assessment
[0495] The TRA, already described in Example 8, reviewed the exemplary preparation G in Example 1 for safety based on the following assumptions.
[0496] (1) Consumer exposure scenarios
[0497] The following assumptions have been made regarding the exposure assessment:
[0498] Product Category: Hand Salad
[0499] Physical state: liquid
[0500] Intended use (suggested use): Apply to hands after washing to keep them in good condition.
[0501] Frequency of use: 730 times / year (hand sanitizer) or 1825 times / year (after washing hands)
[0502] One or more routes of exposure: primarily through skin contact and inhalation of trace amounts of volatile substances.
[0503] Dosage per application: 1.7g
[0504] Exposed area: 302cm² 2
[0505] Duration of exposure: 720 minutes or 192 minutes
[0506] Weight: 11.4kg
[0507] Target group: Children aged one year or older
[0508] (2) Risk characterization of consumer health
[0509] (2.1) Local impact
[0510] Irritation: Under normal and reasonably foreseeable conditions of use, the product is not expected to cause skin or eye irritation. Accidental exposure to the eyes may cause irritation, but such effect is expected to be minimal after rinsing.
[0511] Sensitization: There is no known sensitizing potential of the substance and it is not expected to cause sensitization in most consumers.
[0512] Phototoxicity: Exposure to this product is unlikely to cause phototoxic effects.
[0513] (2.2) Systemic effects
[0514] If the manufacturer's instructions are followed, all ingredients used are cosmetic or of appropriate grade, and the polymers are well-cured. Under normal and reasonably foreseeable conditions of use, this formulation is unlikely to cause visceral damage through the skin. However, the product is intended for use in children one year of age or older who more frequently engage in licking and sucking actions. Although the formulation is not expected to be orally toxic when used as directed, it is like ingesting any non-food substance; however, ingestion of significant amounts of the product will cause discomfort and is harmful even in cases of intentional or repeated ingestion via hand-mouth transfer. It is recommended that the intended user be changed from children one year of age to children three years of age or older. It is also recommended that the product be labeled to ensure its correct use. If any adverse reaction occurs as a result of using this formulation, the signatory should be informed so that the formulation can be further reviewed.
[0515] (2.3) Joint toxicity
[0516] Based on current knowledge, the joint toxicity is unpredictable.
[0517] TRA Conclusion:
[0518] If the manufacturer's instructions are followed, and all ingredients used are cosmetic or of appropriate grade, and the polymer is well cured, it is considered that, with the current level of knowledge, the submitted formulation (composition G) placed on the market is unlikely to pose a significant risk to the health of the intended consumer under normal and reasonably foreseeable conditions of use. This product should be used by children aged 3 years or older. The product should be labeled to ensure its correct use, and the following recommendations are made based on a toxicological point of view.
[0519] Example 17
[0520] Preparations
[0521] Other exemplary formulations (proportions are expressed as percentages by weight (%)) are described in Table 12.
[0522]
[0523]
[0524] Table 12. Other exemplary compositions according to the present invention.
[0525] In some exemplary embodiments, the composition comprises glycerol, caprylyl glycol, and a first component, wherein the first component is ethoxydiethylene glycol. Glycerol, caprylyl glycol, and the first component together form a first component. In some exemplary embodiments, the first component consists essentially of glycerol, caprylyl glycol, and ethoxydiethylene glycol. In other embodiments, the first component comprises glycerol, caprylyl glycol, and ethoxydiethylene glycol in a total of about 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, or 21% by weight, and in other embodiments, 17.4% or 19.0% by weight. In yet another exemplary embodiment, the first component comprises about 8.5%-16% glycerol, about 0.45%-3% caprylyl glycol, and 1%-5% ethoxydiethylene glycol, and the first component is greater than about 13% by weight, as shown in Table 12.
[0526] In some exemplary embodiments and as seen in composition H above, the composition may substantially contain about 13.0% glycerol, about 2.9% octyl glycol, and about 3.1% ethoxydiethylene glycol, and make up to 100% water. In these embodiments, the composition is substantially free of acrylates / C10-30. The composition may further contain about 0.3% panthenol by weight, about 0.2% sodium polyacrylate by weight, about 0.11% ethylhexyl stearate by weight, about 0.04% tridecyl alcohol polyether-6 by weight, about 0.9% ethylhexylglycerin by weight, and about 1.5% 1,2-hexanediol by weight. In this exemplary embodiment, the composition is substantially free of phenoxyethanol, carbomer, sodium dodecylbenzenesulfonate, sodium citrate, silver sulfate, silver, and benzyl alcohol.
[0527] In some exemplary embodiments and as seen in Composition I above, the composition may substantially contain about 11.9% glycerol, about 2.8% octyl glycol, and about 2.7% ethoxydiethylene glycol, and make up to 100% water. The composition may further contain about 0.3% panthenol by weight, about 0.2% sodium polyacrylate by weight, about 0.11% ethylhexyl stearate by weight, about 0.04% tridecyl alcohol polyether-6 by weight, about 0.9% ethylhexylglycerin by weight, and about 1.5% 1,2-hexanediol by weight. In this exemplary embodiment, the composition is substantially free of phenoxyethanol, carbomer, sodium dodecylbenzenesulfonate, sodium citrate, silver sulfate, silver, and benzyl alcohol.
[0528] In some exemplary embodiments and as seen in composition J above, the composition may substantially contain about 13.0% glycerol, about 2.9% caprylyl glycol, and about 3.1% ethoxydiethylene glycol, and make up to 100% water. The composition may further contain about 0.3% panthenol, about 0.3% sodium polyacrylate, about 0.15% ethylhexyl stearate, about 0.05% tridecyl alcohol polyether-6, about 0.9% ethylhexylglycerin, and about 1.5% 1,2-hexanediol by weight. In another exemplary embodiment and as seen in composition J, the composition may further contain about 1% finely ground oat kernels (Avena sativa). In this exemplary embodiment, the composition is substantially free of phenoxyethanol, carbomer, sodium dodecylbenzenesulfonate, sodium citrate, silver sulfate, silver, and benzyl alcohol.
[0529] The method for preparing the exemplary formulations (compositions H, I, and J) is similar to that described in Example 1.
[0530] Example 18
[0531] Viral efficacy against human coronavirus strain 229E
[0532] Standard test method for evaluating the activity of antimicrobial agents against viruses in suspension (ASTM E0152)
[0533] Test microorganism: Human coronavirus, strain 229E, ATCC VR-740
[0534] Host cell: MRC-5 (ATCC CCL-171)
[0535] Test substance: Composition H
[0536] The active ingredients of the tested substances were glycerin, caprylyl glycol, and ethoxydiethylene glycol.
[0537] Test substance dilution: No dilution. Ready-to-use liquid test substance.
[0538] Total organic soil load: No organic soil load was added to the test inoculum.
[0539] Number of repetitions per batch: three
[0540] Contact time: 1 minute
[0541] Exposure temperature: room temperature (20.8℃-21.0℃) and 45%-46% relative humidity (RH)
[0542] Neutralization method: using the dilution method of fetal bovine serum (FBS).
[0543] Test program
[0544] Thaw the stored virus without replenishing the organic matter load in the soil;
[0545] The test material and the virus control material were dispensed into sterile containers in nine equal volumes;
[0546] The test suspension was kept in contact for the time described above and then neutralized by continuous dilution tenfold to a suitable solution.
[0547] Neutralize the virus control suspension in the same manner as the test suspension;
[0548] After neutralization, use standard cell cultures (e.g., TCID50) 50 ) Measurement techniques quantify viral suspensions to determine the level of infectious viruses;
[0549] Incubate the cell culture plates for the period most suitable for the virus-host cell system (e.g., about 7 days);
[0550] After the incubation period, the presence / absence of the test virus and the cytotoxic effect in the assay are scored. Appropriate calculations (e.g., Spearman-Kappa) are performed to determine the viral titer and the level of cytotoxicity of the test substance (if applicable).
[0551] Calculate the Log of the test suspension relative to the control suspension. 10 and percentage decrease;
[0552] Unless otherwise stated, the methods described in this study have not been modified.
[0553] Success criteria
[0554] The following measurements must be met to ensure the acceptability of the antiviral efficacy data:
[0555] Viral titer controls demonstrated a clear and / or typical cytopathic effect on monolayers, unless a detection method other than cytopathic effect was used.
[0556] It has been demonstrated that the test substance can be neutralized with low titers (e.g., 1000–5000 infectious units);
[0557] The quantification of test and control parameters was determined at least four times for each dilution.
[0558] The product performance standards are as follows:
[0559] The logarithmic and percentage reduction of the test virus after exposure to the test substance were calculated; however, there was no minimum reduction level to determine whether a product was “qualified” or “effective.”
[0560] Computation and statistical analysis
[0561] TCID 50 (Tissue Culture Infection Dose) represents the endpoint dilution at which 50% of the cell culture exhibits cytopathic effects due to infection with the tested virus. The endpoint dilution at which 50% of the host cell monolayer exhibits cytotoxicity is called the tissue culture dose (TCD). 50 ). TCID 50 and TCD 50 The Spearman-Kapp method was used to determine and calculate the following:
[0562] The negative logarithm of the endpoint titer = [-negative logarithm of the first dilution] - [((sum of mortality percentages at each dilution / 100) - 0.5) × logarithm of the dilution]
[0563] The result of this calculation is expressed as follows: TCID for the test, virus control, and neutralization control. 50 / 0.1ml (or the volume of the dilution solution used for inoculation), and for the cytotoxicity control, TCD 50 / 0.1ml (or the volume of the diluent used for inoculation).
[0564] Calculation of logarithmic reduction
[0565] The logarithmic decrease in viral titer is calculated as follows:
[0566] Board Recycling Comparison Log 10 TCID 50 -Virus-Test Material Log 10 TCID 50
[0567] Calculation of percentage reduction
[0568] The percentage reduction in viral titer is calculated as follows:
[0569] Percentage decrease = 1 - (C / B) × 100, where:
[0570] B = Average TCID of virus in control suspension 50 .
[0571] C = Virus - Average TCID of virus in test suspension 50 .
[0572] When calculating the logarithm and percentage decrease in viral titer, the presence of cytotoxicity of any test material was taken into account.
[0573] If multiple virus controls and test replicates are performed, the average TCID for each parameter is calculated. 50 The average result was then used to calculate the logarithmic reduction of the viral titer.
[0574] Example 19
[0575] Results of antiviral efficacy against human coronavirus strain 229E
[0576] Test results for the antiviral efficacy of an exemplary composition containing first component #2 (glycerol / octyl glycol / ethoxydiethylene glycol) using the standard test method for evaluating the activity of antimicrobial agents against viruses in suspension as described in Example 18 are shown in Tables 13-16.
[0577] The purpose of the test was to determine the antiviral efficacy of composition B against human coronavirus strain 229E at room temperature (20.8°C–21.0°C and 45%–46% RH) with a contact time of 1 minute and without the addition of organic soil load to the test inoculum.
[0578]
[0579]
[0580] Table 13: Viral titers and viral controls. Keywords: "+" = virus recovered; "0" = no virus recovered and / or no cytotoxicity observed; "T" = cytotoxicity observed; "N / A" = unavailable.
[0581]
[0582] Table 14: Cytotoxicity Control Results. Keywords: "+" = Virus recovered; "0" = No virus recovered and / or no cytotoxicity observed; "T" = Cytotoxicity observed; "N / A" = Not available.
[0583]
[0584] Table 15: Results of the test substance and neutralization control. Keywords: "+" = virus recovered; "0" = no virus recovered and / or no cytotoxicity observed; "T" = cytotoxicity observed; "N / A" = unavailable.
[0585]
[0586] Table 16: Composition H, contact time 1 minute. Keywords: "+" = virus recovered; "0" = no virus recovered and / or no cytotoxicity observed; "T" = cytotoxicity observed; "N / A" = unavailable.
[0587] Table 13 shows the viral titer of 6.75 Log. 10 TCID 50 / 0.1ml, while the viral control showed an average viral titer of 6.05 Log. 10 TCID50 / 0.1ml.
[0588] Table 14 shows that the tissue culture dose for the cytotoxicity control was 2.50 Log. 10 TCD 50 / 0.1ml.
[0589] Table 15 shows the neutralization control evidence for the test substance at 2.50 Log for the tested batches. 10 The lower part is neutralized.
[0590] Table 16 shows that, taking into account the cytotoxicity test results in Table 14 and the neutralization control results in Table 15, the evaluated test substance (exemplary composition H) demonstrated an average of ≥3.55 Log at a 1-minute exposure time. 10 The viral titer decreased (≥99.97%).
[0591] According to tests conducted under the conditions specified in Example 18, the exemplary composition H unexpectedly exhibited excellent antiviral activity at a contact time of 1 minute, indicating that the exemplary composition provides good antiviral efficacy.
[0592] Example 20
[0593] Viral efficacy against coronavirus disease 2019 (COIVD-19)
[0594] method
[0595] 0.1 mL containing 1×10 4 The culture medium for SARS-CoV-2 (COVID-19) virus was mixed with 0.1 mL of exemplary composition H and incubated for 5 minutes. The treated virus was exposed to human kidney cells (approximately 80% confluence) plated at 37°C and supplemented with 5% carbon dioxide (CO2) for 30 minutes. Three serial dilutions were prepared. Infected cells were covered with 0.5 mL of sterile MEM (x2) containing 2% carboxymethyl cellulose and supplemented with fetal bovine serum (10%), pyruvate, and non-essential amino acids. The plates were incubated at 37°C with 5% CO2 supplementation for 48 hours. The plates were then washed with PBS to remove the carboxymethyl cellulose solution and fixed with 4% paraformaldehyde for 30 minutes. Crystal violet (1%) was added to the wells for 15 minutes and washed until plaques were observed. Infected and uninfected cells were used as positive and negative controls, respectively.
[0596] result
[0597] The positive control showed plaque formation, while the negative control showed no plaque formation. The test results showed no plaque formation at the specified time (i.e., 5 minutes of treatment), indicating complete inactivation of the SARS-CoV-2 virus.
[0598] in conclusion
[0599] Based on tests conducted under the conditions specified in Example 20, the exemplary composition H unexpectedly exhibited excellent inactivation activity against SARS-CoV-2 (COVID-19) virus at a contact time of 5 minutes, indicating that the exemplary composition provides good antiviral efficacy.
[0600] Example 21
[0601] Tests for treating dermatitis
[0602] Three patients with dermatitis who did not respond well to typical topical medications were enrolled for testing.
[0603] Case 1
[0604] Patient 1: A 12-year-old Asian adolescent. Overall healthy with no history of health problems except for atopic dermatitis.
[0605] Pre-treatment symptoms: Due to genetic predisposition and immune system dysfunction, the patient frequently experiences moderate to severe dryness, thickening, and cracking of the skin. Patient 1 feels hardening of the skin even when it is not inflamed. During active inflammation, Patient 1 will experience tearing pain and itching, which will usually only respond to strong topical steroids in ointment form (such as betamethasone dipropionate or mometasone dipropionate). The ointment base provides some relief, but it also creates a sticky feeling on the skin, which is particularly unpleasant during hotter weather.
[0606] treat: Figure 1A The typical skin condition of the patient is shown even after prolonged use of existing topical steroids (before treatment with the exemplary composition). Dryness, thickened skin, peeling, and cracking are particularly noticeable around the patient's mouth. Composition H is introduced to patient 1, with only a small amount (less than the size of a 50-cent coin) applied around the oral cavity area. Composition H is applied approximately three times daily for two days.
[0607] Results: Two days after application, his skin inflammation began to subside. Skin texture and thickening showed significant improvement. Skin peeling and cracking were significantly reduced. After one week of application of composition H without the use of any other prescription topical medications, his skin showed significant improvement, such as... Figure 1B As shown in the image. The patient also reported less skin stiffness. An additional benefit was increased self-esteem and confidence due to the significant improvement in the patient's facial appearance.
[0608] Case 2
[0609] Patient 2: A young woman around 30 years old. She works as a project manager for a commercial construction company. Her job is challenging; she needs to travel to different construction sites.
[0610] Pre-treatment symptoms: She had no known medical conditions and no drug or environmental allergies. Due to the pandemic and meeting different people, the patient had been very careful about hand hygiene, using alcohol-based hand sanitizers frequently throughout the day. Shortly afterward, the patient's hands developed significant dryness, thickened skin, erythema, and itching. Patient 2 initially thought it was simply due to dryness from frequent washing. The patient's condition worsened. Patient 2 noticed small blisters forming along the sides of her right fingers. The blisters slowly spread to her right palm and caused intense itching that even woke her from sleep. After seeing a doctor, the patient was diagnosed with hyperhidrosis eczema. Patient 2 was prescribed a strong topical corticosteroid cream. Unfortunately, after a week of corticosteroid treatment, there was only minimal improvement. The patient's right palm became red. Patient 2 also noticed more small blisters forming on her left palm. Figures 2A-2B The condition of her hands is shown after treatment with the mentioned corticosteroids (before treatment with exemplary composition H). Most of the eczematous blisters were scratched open due to intense itching. Patient 2 reported that these small pits felt like active volcanoes and caused a significant burning sensation when Patient 2 used an alcohol-based disinfectant.
[0611] Treatment: As the patient's condition worsened, composition B was introduced to patient 2 as an alternative treatment. Composition H was applied to patient 2's hand (approximately the size of a dollar coin) about three times daily for two weeks.
[0612] Results: Significant improvement was observed after treatment. First, Patient 2 did not experience any burning sensation when using Composition H as a hand sanitizer. Second, after one week, the small blisters were reduced by half and her dry skin subsided. Third, after several weeks, her dyspepsia completely resolved, with no more blisters, itching, or dry skin. Figures 2C-2D The condition of her hand after treatment with composition H is shown.
[0613] Case 3
[0614] Patient 3: A 60-year-old Asian car salesman.
[0615] Pre-treatment symptoms: Patient 3 has a history of hypertension, dyslipidemia, and premature ventricular contractions. Patient 3 has no history of diabetes, seasonal allergies, or congenital dermatitis. The patient's current medications consist only of diltiazem and rosuvastatin. Due to the nature of the patient's work, Patient 3 frequently uses car cleaning products and is exposed to increased levels of allergens (such as volatile organic compounds). Patient 3 has suffered from irritant contact dermatitis for over a decade. The most severe episode occurred after frequent use of alcohol-based hand sanitizers during the COVID-19 pandemic, resulting in a severe flare-up of skin inflammation. Patient 3 has been prescribed various steroid-based compounds. Patient 3 has even been prescribed nonsteroidal immunomodulators. Unfortunately, Patient 3 continues to experience painful skin cracking, thinning, and burning sensations. Figure 3A A photograph shows a patient's finger in its optimal condition after using a potent steroid ointment (before treatment with exemplary composition H).
[0616] Treatment: Introduce composition H as a regular skin cream to the patient, in which only a small amount (less than the size of a 50-cent coin) is applied to the finger, approximately three times a day for one day.
[0617] Results: After one day of standardized application without the use of any prescription topical medications, the skin condition of the patients' fingers further improved, such as... Figure 3B As shown in the image.
[0618] in conclusion
[0619] Exemplary composition H (a non-alcoholic and non-steroidal formulation with antimicrobial properties) showed significant improvement in the skin condition of the above three patients in all cases of different dermatitis conditions and poor response to typical topical agents, indicating that the exemplary composition can be used not only as a skin disinfectant but also as a topical agent for the skin, especially for treating or improving conditions of dermatitis, dryness and / or allergic reactions to alcohol-based disinfectants.
[0620] Exemplary embodiments of the present invention have thus been fully described. Although the description refers to specific embodiments, those skilled in the art will understand that the invention can be practiced with variations in these specific details. Therefore, the invention should not be construed as being limited to the embodiments set forth herein.
Claims
1. An aqueous antibacterial composition, said aqueous antibacterial composition comprising: a) 8.5% - 16% glycerin by weight; b) 0.45% - 3% octyl glycol by weight; c) 1% - 5% by weight of ethoxydiethylene glycol; d) 0% - 2% ethylhexylglycerin by weight; e) 0% to 5% by weight of 1,2-hexanediol; f) 0.1% to 1% panthenol by weight; g) 0.1% to 0.5% sodium polyacrylate by weight; h) 0% to 1% by weight of ethylhexyl stearate; i) 0% to 1% by weight of tridecane alcohol polyether-6; j) 0% to 1% phenoxyethanol by weight; and k) Add water to a total volume of 100% by weight; and The glycerol, octyl glycol, and ethoxydiethylene glycol together constitute more than 13% and less than 25% by weight of the antibacterial composition.
2. The aqueous antibacterial composition according to claim 1, wherein, The composition does not contain alkyl glycerols and / or their alkyl esters.
3. The aqueous antibacterial composition according to claim 1, wherein, The composition does not contain ethylhexylglycerin.
4. The aqueous antibacterial composition according to claim 1, wherein, The aqueous antibacterial composition comprises the following: a) 11.9% - 13% glycerin by weight; b) 2.8% - 2.9% octyl glycol by weight; c) 2.7% - 3.1% by weight of ethoxydiethylene glycol; d) 0.9% ethylhexylglycerin by weight; e) 1.5% by weight of 1,2-hexanediol; f) 0.3% panthenol by weight; g) 0.2% to 0.3% sodium polyacrylate by weight; h) 0.11% to 0.15% by weight of ethylhexyl stearate; i) 0.04% to 0.05% by weight of tridecane alcohol polyether-6; and j) Add water to a total of 100% by weight.
5. The aqueous antibacterial composition according to claim 1, wherein, The composition does not contain sodium polyacrylate.
6. The aqueous antibacterial composition of claim 1, wherein, The composition does not contain simple alcohols, wherein the simple alcohols are short-chain volatile or C1-C4 alcohols.
7. A skin or hand sanitizer comprising an aqueous antibacterial composition as described in any one of claims 1-6.
8. An aqueous antibacterial surface coating comprising the aqueous antibacterial composition as described in any one of claims 1-6.
9. A woven or nonwoven wipe, sponge, or paper towel, wherein the woven or nonwoven wipe, sponge, or paper towel comprises an aqueous antibacterial composition as described in any one of claims 1-6.
10. Use of the aqueous antibacterial composition according to any one of claims 1-6 in the manufacture of disinfectants.
11. An aqueous non-alcoholic disinfectant, said aqueous non-alcoholic disinfectant comprising the following: a) 8.5% - 16% glycerin by weight; b) 0.45% - 3% octyl glycol by weight; c) 1% - 5% by weight of ethoxydiethylene glycol; d) 0% - 2% ethylhexylglycerin by weight; e) 0% to 5% by weight of 1,2-hexanediol; f) 0.1% to 1% panthenol by weight; g) 0.1% to 0.5% sodium polyacrylate by weight; h) 0% to 1% by weight of ethylhexyl stearate; i) 0% to 1% by weight of tridecane alcohol polyether-6; j) 0% to 1% by weight of phenoxyethanol; and k) Add water to a total volume of 100% by weight; and The total amount of the glycerol, octyl glycol and ethoxydiethylene glycol is 13%-25% by weight of the disinfectant.
12. The aqueous non-alcoholic disinfectant as described in claim 11, wherein, The disinfectant does not contain alkyl glycerol and / or its alkyl esters.
13. The aqueous non-alcoholic disinfectant as described in claim 11, wherein, The disinfectant does not contain ethylhexylglycerin.
14. The aqueous non-alcoholic disinfectant as described in claim 11, wherein, The total amount of the glycerol and the caprylyl glycol is 15% by weight.
15. The aqueous non-alcoholic disinfectant as described in claim 11, wherein, The total amount of the glycerol, the octyl glycol and the ethoxydiethylene glycol is 19% by weight.
16. The aqueous non-alcoholic disinfectant as described in claim 11, wherein, The total amount of the glycerol, the octyl glycol and the ethoxydiethylene glycol is 16.4% by weight.
17. The aqueous non-alcoholic disinfectant as described in claim 11, wherein, The total amount of the glycerol, the octyl glycol and the ethoxydiethylene glycol is 20.8% by weight.
18. The aqueous non-alcoholic disinfectant as described in claim 11, wherein, The total amount of the glycerol, the octyl glycol and the ethoxydiethylene glycol is 17.4% - 19.0% by weight.
19. The aqueous non-alcoholic disinfectant as described in claim 11, wherein, The aqueous non-alcoholic disinfectant comprises the following: a) 11.9% - 13% glycerin by weight; b) 2.8% - 2.9% octyl glycol by weight; c) 2.7% - 3.1% by weight of ethoxydiethylene glycol d) 0.9% ethylhexylglycerin by weight; e) 1.5% by weight of 1,2-hexanediol; f) 0.3% panthenol by weight; g) 0.2% to 0.3% sodium polyacrylate by weight; h) 0.11% to 0.15% by weight of ethylhexyl stearate; i) 0.04% to 0.05% by weight of tridecane alcohol polyether-6; and j) Add water to a total of 100% by weight.
20. Use of the composition of any one of claims 1-6 in the manufacture of a medicament for alleviating or treating at least one skin condition in a subject in need, said skin condition being selected from the group consisting of eczematous vesicles, dry skin, thickened skin, thinned skin, cracked skin, peeling skin, dermatitis, pruritus, hyperhidrosis, skin hypersensitivity to alcohol, skin stiffness, and erythema.
21. The use as described in claim 20, wherein, Skin inflammation includes irritant contact dermatitis and atopic dermatitis.
22. The use as described in claim 20, wherein, The composition is administered locally.
23. Use of the aqueous non-alcoholic disinfectant of any one of claims 11-19 in the manufacture of a medicament for alleviating or treating at least one skin condition in a subject in need, said skin condition being selected from the group consisting of eczematous vesicles, dry skin, thickened skin, thinned skin, cracked skin, peeling skin, dermatitis, pruritus, diaphoretic eczema, skin hypersensitivity to alcohol, skin stiffness, and erythema.
24. The use as described in claim 23, wherein, Skin inflammation includes irritant contact dermatitis and atopic dermatitis.
25. The use as described in claim 23, wherein, The disinfectant is applied topically.
